Prepivotal Evaluation of the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Patients With Type 1 Diabetes
Phase: NA
Conditions: Type 1 Diabetes Mellitus
Sponsor: Insulet Corporation

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 1 
 
 
Prepivotal Evaluation of the Safety and Effectiveness of the 
Omnipod Horizon™ Automated Glucose Control System in 
Patients with Type 1 Diabetes 
 
 
IDE G190267 
Version 2.3 
November 14, 2019 
 
 
Insulet Corporation 
100 Nagog Park 
Acton, MA 01720 
 
 
 
 
Confidentiality Statement: 
The information in this document contains trade secrets and commercial information that are 
privileged or confidential and may not be disclosed unless such disclosure is required by 
applicable law or regulations. In any event, persons to whom the information is disclosed must 
be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on the disclosure shall apply equally to all future information supplied to 
you, which is indicated as privileged or confidential. 
 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 2 
PROTOCOL APPROVAL 
 
 
 
Prepivotal Evaluation of the Safety and Effectiveness of the 
Omnipod Horizon™ Automated Glucose Control System in 
Patients with Type 1 Diabetes 
 
IDE G190267 
Version 2.3 
November 14, 2019 
 
 
 
______________________________________ 
Trang Ly MBBS FRACP PhD - SVP, Clinical and  
Medical Director, Insulet Corporation 
 
 
 
 
        _____________________ 
        Date 
 
 
 
______________________________________ 
Bonnie Dumais, RN – Director of Clinical Affairs,  
Insulet Corporation 
 
 
 
 
        _____________________ 
        Date 
 
 
 
______________________________________ 
Julie Perkins - Senior Director, Quality and Regulatory,  
Insulet Corporation 
 
 
 
 
        _____________________ 
        Date 
 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 3 
INVESTIGATOR STATEMENT 
 
Prepivotal Evaluation of the Safety and Effectiveness of the 
Omnipod Horizon™ Automated Glucose Control System in 
Patients with Type 1 Diabetes 
IDE G190267 
November 14, 2019 
Version 2.3 
I agree to conduct the above referenced clinical study protocol in accordance with the 
design and specific provisions as designated in this protocol, the signed agreement with 
the Sponsor, applicable FDA regulations, and any conditions of approval imposed by an 
Institutional Review Board (IRB) or Food and Drug Administration (FDA). Modifications 
to the study protocol are acceptable only in the form of a protocol amendment, except 
when necessary to protect the safety, rights, or welfare of subjects. I agree to await 
Institutional Review Board (IRB) and Insulet approval for the protocol, informed consent 
and documentation to be presented to subjects before initiating the study pursuant to 21 
CFR Part 56, to obtain informed consent from subjects prior to their enrollment into the 
study pursuant to 21 CFR Part 50, to collect and record data as required by this 
protocol and case report forms, to report non serious and serious adverse events that 
may occur for any subject participating in this study under my care, to report product 
complaints for any of the devices utilized in this protocol, and to maintain study related 
documentation (regulatory documentation) for the period of time required. I agree to 
supervise all utilization of investigational study devices and to ensure their usage is only 
in connection with the Study. I agree to provide a Financial Disclosure Statement to 
Sponsor and will also notify Sponsor if my disclosed financial information changes 
during the Study and up to one year following the closure of the Study. I have read and 
understand the contents of this protocol. I agree to follow and abide by the requirements 
set forth in this document. 
I understand the information in this document contains trade secrets and commercial 
information that are privileged or confidential and may not be disclosed unless such 
disclosure is required by applicable law or regulations. In any event, persons whom the 
information is disclosed must be informed that the information is privileged or 
confidential and may not be further disclosed by them. These restrictions on disclosure 
will apply equally to all future information supplied to me, which is indicated as 
privileged or confidential. 
___________________________________  
Clinical Site Investigator Name (print) 
 
___________________________________  
 
__________________ 
Clinical Site Investigator Signature 
 
 
 
 
Date 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 4 
PRINCIPAL CONTACTS 
 
Sponsor Contacts:  
Trang Ly, MBBS FRACP PhD 
SVP, Clinical and Medical Director 
Insulet Corporation 
100 Nagog Park 
Acton, MA 01720 
Office: 978-600-7628 
E-mail: tly@insulet.com 
 
 
 
Julie Perkins 
Senior Director, Quality and Regulatory 
Insulet Corporation 
100 Nagog Park 
Acton, MA 01720 
Office: 978-600-7951 
E-mail: jperkins@insulet.com  
 
Protocol Chairs: 
 
Bruce Buckingham, MD 
 
 
 
 
Professor, Pediatrics 
Division of Endocrinology and Diabetes 
 
Stanford School of Medicine 
 
 
 
 
780 Welch Road 
Palo Alto, CA 94305 
 
E-mail: bbendo@stanford.edu  
 
Sue Brown, MD 
Associate Professor of Medicine 
Division of Endocrinology 
University of Virginia 
Centers for Diabetes Technology 
560 Ray C. Hunt Drive, 3rd Floor 
Charlottesville, VA  22908 
Email: sab2f@virginia.edu 
 
 
 
 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 5 
TABLE OF CONTENTS 
TITLE PAGE ......................................................…........................................................................1 
PROTOCOL APPROVAL ............................................................................................................... 2 
INVESTIGATOR STATEMENT ...................................................................................................... 3 
PRINCIPAL CONTACTS ................................................................................................................ 4 
TABLE OF CONTENTS ................................................................................................................. 5 
PROTOCOL SUMMARY ................................................................................................................ 8 
GLOSSARY OF ACRONYMS ...................................................................................................... 13 
1 
INTRODUCTION ................................................................................................................. 15 
2 
OMNIPOD HORIZON™ SYSTEM STUDY DEVICE OVERVIEW ...................................... 16 
2.1 
Device Description of the Omnipod Horizon™ System ................................. 16 
3 
HORIZON™ DATA PORTAL ............................................................................................... 20 
3.1 
Remote Monitoring........................................................................................ 20 
4 
RESULTS FROM FEASIBILITY STUDIES .......................................................................... 20 
5 
STUDY SUMMARY ............................................................................................................. 20 
5.1 
Study Purpose .............................................................................................. 20 
5.2 
Study Design ................................................................................................ 21 
6 
OBJECTIVES AND ENDPOINTS ........................................................................................ 28 
6.1 
Safety Objective ............................................................................................ 28 
6.1.1 
Primary Safety Endpoint ........................................................................... 28 
6.1.2 
Secondary Safety Endpoints ..................................................................... 28 
6.2 
Primary Effectiveness Objective.................................................................... 28 
6.2.1 
Primary Effectiveness Endpoint ................................................................ 28 
6.3 
Secondary Effectiveness Objective ............................................................... 28 
6.3.1 
Secondary Effectiveness Endpoints .......................................................... 28 
7 
SCREENING AND ELIGIBILITY .......................................................................................... 29 
7.1 
Visit 1 ............................................................................................................ 29 
8 
STANDARD THERAPY - PHASE 1 ..................................................................................... 33 
8.1 
Visit 2 ............................................................................................................ 34 
8.2 
Visit 3 ............................................................................................................ 35 
9 
HYBRID CLOSED-LOOP - PHASE 2 .................................................................................. 36 
9.1 
Target BG Challenges .................................................................................. 36 
9.2 
Hotel/Rental House Environment .................................................................. 37 
9.3 
Visit 4 ............................................................................................................ 37 
9.4 
Visit 5 ............................................................................................................ 38 
9.5 
Visit 6 ............................................................................................................ 39 
9.6 
Visits 7, 8 and 9 ............................................................................................ 39 
9.7 
Visit 10 (End of Study) .................................................................................. 39 
9.8 
Unscheduled Visits ....................................................................................... 40 
9.9 
Early Withdrawal ........................................................................................... 41 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 6 
9.10 
Lost to Follow-up .......................................................................................... 42 
10 
SPONSOR REPRESENTATIVES ....................................................................................... 42 
11 
SAFETY ............................................................................................................................... 42 
11.1 
Types of Known Risks and Benefits .............................................................. 42 
11.2 
Hypoglycemia/Hyperglycemia ....................................................................... 43 
11.3 
Adverse Events ............................................................................................. 43 
11.3.1 
Definitions ............................................................................................. 43 
11.3.2 
Reportable Adverse Events ................................................................... 45 
11.3.3 
Hypoglycemic Events ............................................................................ 46 
11.3.4 
Hyperglycemic/Ketotic Events ............................................................... 46 
11.3.5 
Relationship of Adverse Event to Investigational Device ....................... 47 
11.3.6 
Severity (Intensity) of Adverse Events ................................................... 47 
11.3.7 
Outcome of Adverse Events .................................................................. 48 
11.4 
Reportable Device Issues ............................................................................. 48 
11.5 
Timing of Event Reporting............................................................................. 49 
11.6 
Safety Oversight ........................................................................................... 50 
11.7 
Stopping Criteria ........................................................................................... 50 
11.7.1 
Participant Discontinuation of Study Participation .................................. 50 
11.7.2 
Criteria for Suspending or Stopping Overall Study ................................ 50 
11.8 
Data Safety Monitoring Board (DSMB).......................................................... 51 
11.9 
Medical Monitor ............................................................................................ 52 
12 
STATISTICAL CONSIDERATIONS ..................................................................................... 53 
12.1 
Objectives and Endpoints ............................................................................. 53 
12.1.1 
Safety Objective .................................................................................... 53 
12.1.2 
Primary Effectiveness Objective ............................................................ 53 
12.1.3 
Secondary Effectiveness Objective ....................................................... 53 
12.1.4 
Secondary Effectiveness Endpoints ...................................................... 53 
12.2 
Sample Size ................................................................................................. 54 
12.3 
Analysis Sets ................................................................................................ 54 
12.3.1 
ITT (Intention to Treat) Analysis Set ...................................................... 54 
12.3.2 
mITT (modified Intention to Treat) Analysis Set ..................................... 54 
12.3.3 
PP (Per-Protocol) Analysis Set .............................................................. 54 
12.4 
Analysis of Primary and Secondary Effectiveness Endpoints ........................ 55 
12.5 
Additional Data Analyses .............................................................................. 55 
12.6 
Safety Analyses ............................................................................................ 56 
12.6.1 
Evaluation of Adverse Events ................................................................ 56 
12.6.2 
Evaluation of Device Deficiencies ......................................................... 56 
12.7 
Baseline Characteristics ............................................................................... 56 
12.8 
General Statistical Methods .......................................................................... 56 
12.9 
Missing Data ................................................................................................. 57 
12.10 
Statistical Software ................................................................................... 57 
13 
DATA HANDLING AND QUALITY ASSURANCE ............................................................... 57 
13.1 
Electronic Case Report Forms (eCRFs) ........................................................ 57 
13.2 
Electronic Device Outputs ............................................................................. 57 
13.2.1 
PDM Data ............................................................................................. 57 
13.2.2 
CGM Data ............................................................................................. 58 
13.2.3 
BG and Ketone Meter Data ................................................................... 58 
13.3 
Subject Identifiers ......................................................................................... 58 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 7 
13.4 
Monitoring Responsibilities ........................................................................... 58 
13.5 
Inspection of Records ................................................................................... 58 
13.6 
Study Record Retention ................................................................................ 59 
13.7 
Device Accountability .................................................................................... 59 
14 
STUDY ETHICS AND CONDUCT ....................................................................................... 59 
14.1 
Role of the Sponsor ...................................................................................... 59 
14.2 
Ethical Conduct of the Study ......................................................................... 59 
14.3 
Institutional Review Board (IRB) ................................................................... 59 
14.4 
Informed Consent ......................................................................................... 60 
14.5 
Confidentiality ............................................................................................... 60 
14.6 
Modification of the Protocol ........................................................................... 61 
14.7 
Protocol Deviations ....................................................................................... 61 
14.8 
Study Reporting Requirements ..................................................................... 62 
14.9 
Selection of Investigators .............................................................................. 62 
14.9.1 
Financial Disclosure .............................................................................. 62 
14.9.2 
Investigator Documentation ................................................................... 62 
14.10 
Clinical Site Training ................................................................................. 63 
14.11 
Device Use ............................................................................................... 63 
14.12 
Device Returns ......................................................................................... 63 
14.13 
Policy for Publication and Presentation of Data ......................................... 63 
14.14 
Sponsor or Regulatory Agency Termination of the Study .......................... 64 
REFERENCES ............................................................................................................................. 65 
APPENDIX .................................................................................................................................... 68 
 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 8 
PROTOCOL SUMMARY 
Protocol title 
Prepivotal evaluation of the safety and effectiveness of the Omnipod Horizon™ 
Automated Glucose Control System in patients with type 1 diabetes 
Protocol ID 
G190267 
Purpose 
To evaluate the safety and effectiveness of the Omnipod Horizon™ Automated 
Glucose Control System in patients with type 1 diabetes.  
Design 
This study is a single-arm, multi-center, prospective clinical study  
Enrollment 
Up to 48 subjects will be enrolled in the study in order to obtain a minimum of 
36 evaluable subjects. The study will consist of two phases: 
 
1) 14-day standard therapy phase, followed by; 
2) 14-day hybrid closed-loop phase 
 
Subjects will be enrolled across 6-8 clinical study sites. The 36 evaluable 
subjects will be comprised of two age cohorts as follows: 
 
• 
18 subjects aged 6-13.9 years  
• 
18 subjects aged 14-70 years 
Indication 
The Omnipod Horizon™ Automated Glucose Control System is a single 
hormone insulin delivery system intended for the management of diabetes in 
persons requiring insulin. Continuous subcutaneous insulin infusion may be 
delivered by user-defined settings (manual mode) or automatically adjusted in 
response to feedback from a continuous glucose monitor (CGM).  
 
The Omnipod Horizon™ System can automatically increase insulin delivery 
based on CGM sensor glucose values and can decrease or suspend delivery of 
insulin when the glucose value falls below or is predicted to fall below 
predefined threshold values. The Omnipod HORIZON™ System is 
interoperable with compatible iCGMs and ACE pumps. 
 
The Omnipod Horizon™ System is designed to assist patients with diabetes in 
achieving glycemic targets set by their health care providers.   
Study duration 
The study is expected to be completed within 6-months which includes clinical 
site initiation to completion of all data entry and monitoring procedures. 
Investigational 
devices 
The Omnipod Horizon™ Automated Glucose Control System is comprised of 
the following components: 
• 
Omnipod Horizon™ tubeless, insulin delivery alternate controller enabled 
(ACE) pump (Pod) with the Horizon™ algorithm  
• 
Omnipod Horizon™ Personal Diabetes Manager (PDM) which is a 
Samsung J3 locked down Android device that operates the Omnipod 
Horizon™ App.  
Non-
investigational, 
commercially 
available devices 
• 
Dexcom G6 - Continuous Glucose Monitoring (CGM) system  
• 
Contour® Next One blood glucose meter (Ascensia Diabetes Care, 5 Wood 
Hollow Road, Parsippany, NJ 07054 USA) 
• 
Precision Xtra ketone meter (Abbott Diabetes Care Inc., 1360 South Loop 
Road, Alameda, CA 94502 USA) 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 9 
Safety objective 
To evaluate the safety of the Omnipod Horizon™ Automated Glucose Control 
System in patients with type 1 diabetes  
Primary safety 
endpoint 
Proportion of subjects with serious device-related adverse events 
Secondary safety 
endpoints 
• 
Proportion of subjects with severe hypoglycemia during hybrid closed-
loop 
• 
Proportion of subjects with diabetic ketoacidosis (DKA) during hybrid 
closed-loop 
Primary 
effectiveness 
objective 
To evaluate the effectiveness of the Omnipod Horizon™ Automated Glucose 
Control System 
Primary 
effectiveness 
endpoints 
Percentage of time in range (70-180 mg/dL) during hybrid closed-loop 
compared to standard therapy for: 
 
• 
Target blood glucose (BG) challenge days (approximately hybrid 
closed-loop days 1-9) 
• 
Non-challenge days (approximately hybrid closed-loop days 10-14) 
• 
Overall (hybrid closed-loop days 1-14) 
Secondary 
effectiveness 
objective 
To evaluate additional glycemic measures of effectiveness of the Omnipod 
Horizon™ Automated Glucose Control System 
Secondary 
effectiveness 
endpoints 
The secondary objective will be evaluated using the following per subject 
endpoints: 
 
• 
Glucose metrics from system CGM during the hybrid closed-loop phase 
will be compared to the standard therapy phase during the day, 
overnight, and overall:  
 
• 
Mean glucose 
• 
% of time in range 70-180 mg/dL 
• 
% of time in range 70-140 mg/dL 
• 
% of time > 180 mg/dL 
• 
% of time ≥ 250 mg/dL 
• 
% of time ≥ 300 mg/dL 
• 
% of time < 70 mg/dL 
• 
% of time < 54 mg/dL 
• 
Standard deviation 
• 
Coefficient of variation 
 
• 
Glucose management indicator (GMI) based on overall mean glucose 
• 
Percentage of time in hybrid closed-loop as proportion of overall device 
usage time 
• 
Insulin requirements during the hybrid closed-loop phase will be 
compared to the standard therapy phase: 
 
• 
Total daily insulin (TDI) (units, units/kg) 
• 
Total daily basal insulin (units, units/kg) 
• 
Total daily bolus insulin (units, units/kg) 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 10 
Eligibility criteria 
Inclusion Criteria 
Subjects must meet all of the following criteria to be included in the study: 
1. Age at time of consent/assent 6-70 years 
2. Subjects aged < 18 years must be living with parent/legal guardian 
3. Diagnosed with type 1 diabetes for at least 6 months. Diagnosis is based on 
investigator’s clinical judgment. 
4. Deemed appropriate for pump therapy per investigator’s assessment taking 
into account previous history of severe hypoglycemic and hyperglycemic 
events, and other comorbidities 
5. Investigator has confidence that the subject can successfully operate all 
study devices and is capable of adhering to the protocol 
6. Willing to use only the following types of insulin during the study: Humalog, 
Novolog, Admelog, or Apidra during the study 
7. Must be willing to set target glucose between 130-150 mg/dL each for 
approximately 72-hours on predefined days during the hybrid closed-
loop phase  
8. Must be willing to extend their participation into the pivotal study if they 
continue to meet the protocol criteria 
9. Willing to wear the system continuously throughout the study 
10. A1C <10% at screening visit 
11. Must be willing to use the Dexcom App on the Omnipod Horizon™ PDM as 
the sole source of Dexcom data (with the exception of the Dexcom Follow 
App) during the hybrid closed-loop phase 
12. Subjects scoring ≥ 4 on the Clarke Questionnaire must agree to have an 
overnight companion, defined as someone who resides in the same home 
or building as the study subject and who can be available overnight 
13. Able to read and speak English fluently 
14. Subject must be in an AT&T covered area 
15. Willing and able to sign the Informed Consent Form (ICF) and/or has a 
parent/guardian willing and able to sign the ICF. Assent will be obtained 
from pediatric and adolescent subjects aged < 18 years per State 
requirements. 
 
Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from the study: 
1. A medical condition, which in the opinion of the investigator, would put the 
subject at an unacceptable safety risk 
2. History of severe hypoglycemia (as defined in Section 11.3.3) in the past 6 
months 
3. History of DKA (as defined in Section 11.3.4) in the past 6 months, 
unrelated to an intercurrent illness, infusion set failure or initial diagnosis 
4. Diagnosed with sickle cell disease 
5. Diagnosed with hemophilia or any other bleeding disorders 
6. Plans to receive blood transfusion over the course of the study 
7. Currently diagnosed with anorexia nervosa or bulimia 
8. Acute or chronic kidney disease (e.g. estimated GFR < 45) or currently on 
hemodialysis 
9. History of adrenal insufficiency 
10. Has taken oral or injectable steroids within the past 8 weeks or plans to 
take oral or injectable steroids during the course of the study 
11. Unable to tolerate adhesive tape or has any unresolved skin condition in the 
area of sensor or pump placement 
12. Plans to use insulin other than U-100 insulin intended for use in the study 
device during the course of the study 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 11 
13. Use of non-insulin anti-diabetic medication other than metformin (e.g. GLP1 
agonist, SGLT2 inhibitor, DPP-4 inhibitor, pramlintide) 
14. Current or known history of coronary artery disease that is not stable with 
medical management, including unstable angina, or angina that prevents 
moderate exercise despite medical management, or a history of myocardial 
infarction, percutaneous coronary intervention, or coronary artery bypass 
grafting within the previous 12 months.  
15. For subjects >50 years old or with diabetes duration >20 years, abnormal 
electrocardiogram consistent with increased risk of arrhythmia, ischemia, or 
prolonged QTc interval (> 450 ms)  
16. Thyroid Stimulating Hormone (TSH) is outside of normal range with 
clinical signs of hypothyroidism or hyperthyroidism 
17. Pregnant or lactating, or is a woman of childbearing potential and not on 
acceptable form of birth control (acceptable includes abstinence, condoms, 
oral/injectable contraceptives, IUD or implant) 
18. Participation in another clinical study using an investigational drug or device 
within the preceding 30-days or intends to participate during the study 
period  
19. Unable to follow clinical protocol for the duration of the study or is otherwise 
deemed unacceptable to participate in the study per the investigator’s 
clinical judgment. 
Study schedule 
overview 
The study schedule consists of the following two phases: 
 
1) 14-day outpatient standard therapy phase followed by; 
2) 14-day hybrid closed-loop phase 
 
Following subject screening, enrollment, and device training, subjects will 
commence the outpatient standard therapy phase of the study.  
 
Current Dexcom G6 CGM users may provide data from a 14-day period within 
the last 30-days. The CGM data meeting the minimum criteria must be the most 
recent data from the last 30-days. For non-G6 users, subjects will wear a study 
CGM, in blinded mode, to record glucose measurements over 14-days while 
subjects manage their diabetes at home per their usual routine and remaining 
on their current MDI or pump therapy, and sensor, if applicable, for 14-days.  
 
After completion of the standard therapy phase, subjects will be trained on the 
system and transition to the hybrid closed-loop phase initiating treatment with 
the Omnipod Horizon™ System. For the hybrid closed-loop phase, subjects will 
be divided into two groups: 
 
Group 1: 
 
1. N=16 subjects aged 6-70 years will participate in the hybrid closed-loop 
phase for the first 2-days while in a supervised hotel/rental house 
environment and then transition to 12-day outpatient environment 
o 
N=8 subjects aged 6-13.9 years 
o 
N=8 subjects aged 14-70 years 
Group 2: 
 
2. N=20 subjects aged 6-70 years will participate in the hybrid closed-loop 
phase in a 14-day outpatient environment 
o 
N=10 subjects aged 6-13.9 years 
o 
N=10 subjects aged 14-70 years 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 12 
 
The first group of subjects (n=16) will commence the hybrid closed-loop phase 
in the hotel setting. On study day-3, subjects will transition to the outpatient 
setting for the remaining 12-days. After all subjects from the first group have 
completed the 2-day hotel phase, the second group of subjects may commence 
hybrid closed-loop. The second group of subjects (n=20) will use hybrid closed-
loop in the outpatient setting for 14-days.  
 
All subjects will participate in target glucose challenges during the hybrid 
closed-loop phase. In total, all subjects will complete 14-days of hybrid closed-
loop control, with approximately 72-hours spent at target blood glucoses levels 
set to 130mg/dL, 140mg/dL and 150mg/dL, respectively. 
 
Clinical site staff will receive alerts through a remote monitoring system during 
the study. 
 
After each subject in the prepivotal study has successfully completed 14-days 
of hybrid-closed loop, they may immediately transition to and enroll in the 
pivotal study bypassing standard therapy (Phase 1) and continuing with the 
pivotal hybrid closed-loop phase (Phase 2). Remote monitoring will be 
discontinued as each subject enrolls in the pivotal study. 
 
After 16-subjects from the prepivotal study have completed a minimum of 10-
days of hybrid-closed-loop, the Data Safety Monitoring Board (DSMB) will 
convene and if the system is determined to be safe, the pivotal study may open 
enrollment to additional subjects for the hybrid closed-loop phase (Phase 2). 
 
The standard therapy phase (Phase 1) of the pivotal study may commence in 
parallel to the prepivotal study.    
 
 
 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 13 
GLOSSARY OF ACRONYMS 
ACE 
Alternate Controller Enabled 
ADA 
American Diabetes Association 
ADE 
Adverse Device Effect 
AID 
Automated Insulin Delivery 
AE 
Adverse Event 
BG 
Blood Glucose 
BLE 
Bluetooth Low Energy 
CFR 
Code of Federal Regulations 
CGM 
Continuous Glucose Monitoring 
CRA 
Clinical Research Associate 
CRO 
Contract Research Organization 
CV 
Curricula Vitae 
DD 
Device Deficiency 
DKA 
Diabetic Ketoacidosis 
dL 
Deciliter 
DSMB 
Data Safety Monitoring Board 
eCRF 
Electronic Case Report Form 
EDC 
Electronic Data Capture 
EGV 
Estimated Glucose Value 
FDA 
Food and Drug Administration 
GMI 
Glucose Management Indicator 
HDP 
Horizon Data Portal 
HIPAA 
Health Insurance Portability and Accountability Act 
ICF 
Informed Consent Form 
IOB 
Insulin on Board 
IRB 
Institutional Review Board 
ITT 
Intention to Treat 
MD 
Doctor of Medicine 
MDI 
Multiple Daily Injections 
mg 
Milligram 
mITT 
Modified Intention to Treat 
mmol 
Millimole 
MPC 
Model Predictive Control 
NGSP 
National Glycohemoglobin Standardization Program 
PDM 
Personal Diabetes Manager 
PHI 
Protected Health Information 
POC 
Point of Care 
pMPC 
Personalized Model Predictive Control 
PP 
Per Protocol 
PTOF 
Pump Therapy Order Form 
SADE 
Serious Adverse Device Effect 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 14 
SAE 
Serious Adverse Event 
SMP 
Safety Management Plan 
TSH 
Thyroid Stimulating Hormone 
TDI 
Total Daily Insulin 
UADE 
Unanticipated Adverse Device Effect 
 
 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 15 
1 
INTRODUCTION 
Diabetes is a disorder affecting the normal homeostatic regulation of blood glucose. In 
type 1 diabetes, insulin insufficiency occurs due to autoimmune destruction of the beta 
cells in the pancreas resulting in persistently elevated glucose. The long-term effects of 
elevated blood glucose or hyperglycemia may result in a range of microvascular 
complications including retinopathy, nephropathy, and neuropathy. Diabetes is the 
leading cause of blindness, kidney disease, and amputation in the United States.1 
The risk for long-term complications of diabetes can be reduced, however, by 
minimizing patient exposure to hyperglycemia and maximizing the time in euglycemia. 
The landmark Diabetes Control and Complications Trial published in 1993 found that 
maintenance of near normal glucose levels reduced the risk of long-term microvascular 
complications. In 2005, the publication of the Epidemiology of Diabetes Interventions 
and Complications study found that despite the multifactorial etiology of heart disease, 
intensive insulin therapy in patients with type 1 diabetes was shown to reduce the 
incidence of nonfatal myocardial infarction, stroke, and death from cardiovascular 
disease.2 
Unfortunately, efforts to minimize hyperglycemia and maximize euglycemia are 
invariably accompanied by episodes of hypoglycemia. Indeed, the justifiable fear of 
hypoglycemia is often described as the single most significant barrier to improved 
glucose control in patients with diabetes.3 A paper by Weinstock et. al. reported on data 
collected by the T1D Exchange and found an annual incidence of 11.8% of one or more 
severe hypoglycemic events defined as a seizure or loss of consciousness. The annual 
incidence of severe hypoglycemic events increased to 18.6% in patients with diabetes 
duration greater than 40 years.4 
Two other recent papers have highlighted the effect of acute and chronic complications 
on the longevity of patients with diabetes. Livingstone et. al. found premature death in a 
Scottish registry of patients with diabetes of 11 years in males and 13 years in females.5 
Lind et. al. found a twofold increase in mortality in a Swedish registry compared with 
age-matched non-diabetic cohorts even in patients with recommended levels of 
glycemic control (A1C < 7.0%).6The most recent treatment guidelines from the 
American Diabetes Association now recommend that adults with type 1 diabetes should 
aim for target A1C levels of 7.0% and that children and adolescents should aim for 
target A1C levels of 7.5%.7 These recommendations are equivalent to a mean blood 
glucose of 154 mg/dL in adults and 169 mg/dL in children and adolescents compared 
with mean blood glucose in patients without diabetes of 100 mg/dL or less.8 
The last 20 years have seen a number of significant improvements in diabetes care, 
most notably the advent of faster analog insulins, the widespread use of insulin pumps 
and the introduction of continuous glucose monitoring systems. Despite these 
advances, diabetes data registries continue to show that the majority of patients are 
unable to meet recommended glycemic targets with available medication and 
technology. In the 2012 report from the T1D Exchange Registry, Beck et. al. found the 
average A1C across all ages greater than 8.0% or, equivalently, greater than 183 
mg/dL and only 30% of patients met the ADA target A1C of 7.0% (adults) and 7.5% 
(children).9 A more recent paper from the T1D Exchange Registry by Foster et. al. 
comparing the 2016-2018 cohort with 2010-2012 cohort indicated that among the 9,657 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 16 
participants that had data in both cohorts and at least 3 years of diabetes duration in 
2010-2012, mean HbA1c was higher in the 2016-2018 cohort. The increase in HbA1c 
over time was predominately seen in adolescents and young adults. The American 
Diabetes Association (ADA) HbA1c target as of 2018 of < 7.5% for children and 
adolescents was achieved by only a small percentage of youth < 18 years of age (17%); 
only 21% of adults achieved the ADA treatment goal of < 7.0%.10 
The current dilemma of persistent poor diabetes outcomes despite significant 
improvements in diabetes technology such as modern blood glucose meters, insulin 
pumps and continuous glucose monitoring systems is summarized in the FDA 
Guidance Document on Artificial Pancreas Device Systems: “Even with the aid of these 
devices, maintaining blood glucose concentrations within a suggested optimal range is 
a daily struggle for people living with diabetes mellitus and the risk of hypoglycemia 
associated with attempts at improved glycemic control remains an ever-present 
danger”.11 
Insulet has developed the Omnipod Horizon™ Automated Glucose Control System 
(hereafter named Omnipod Horizon™ System or Omnipod Horizon™) which is similar 
in function to the systems described in the FDA guidance document dated November 9, 
2012. The system provides automated glucose control at all times, but for optimum 
performance, requires user input for meal boluses. The commercial system will consist 
of an Omnipod® tubeless, insulin delivery ACE pump, a Personal Diabetes Manager 
(PDM), and the Dexcom G6 CGM. The control algorithm will reside on the Pod.  
This prepivotal study is designed to evaluate the safety and effectiveness of the 
Omnipod Horizon™ System while in a more closely supervised environment prior to 
commencing the pivotal study. Target BG challenges will be conducted to ensure 
exposure to stressors during the study. 
 
2 
OMNIPOD HORIZON™ SYSTEM STUDY DEVICE OVERVIEW 
This study will evaluate the safety and effectiveness of the Omnipod Horizon™ System. 
The Omnipod Horizon™ System is a hybrid closed-loop automated insulin delivery 
(AID) system developed by Insulet.  
2.1 Device Description of the Omnipod Horizon™ System 
The Omnipod Horizon™ System intended for commercialization is composed of three 
primary components as shown in Figure 1. 
• 
Omnipod Horizon™ Controller – Horizon App (PDM) and Algorithm 
• 
Omnipod Horizon™ ACE Pump – Pod  
• 
iCGM – Dexcom G6 
The Omnipod Horizon™ System will provide automated insulin delivery when 
connected to CGM. The system is expected to reduce hypoglycemia without incurring 
an unacceptable increase in hyperglycemia and mean glucose. The system is also 
expected to reduce the extent and magnitude of hyperglycemia associated with meals. 
Optimal post-prandial control requires the user to deliver meal boluses as in current 
open-loop therapy, but the normal operation of the control algorithm will be expected to 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 17 
compensate for mismatched meal boluses and prevent prolonged hyperglycemia. The 
system uses a control-to-target strategy that attempts to achieve and maintain a set 
target glucose level. 
 
Figure 1:  System components of the Omnipod Horizon™ System 
2.1.1. Omnipod Horizon™ Controller (App and Algorithm) 
 
The Omnipod Horizon™ Controller is composed of two parts: the Horizon application 
(“app”) and the model predictive control (MPC) algorithm on the Pod. The MPC 
algorithm provides insulin micro-boluses once every 5 minutes based upon the 
predicted glucose over a 60-minute prediction horizon. Optimal post-prandial control will 
require the user to give meal boluses in the same manner as current pump therapy, but 
normal operation of the MPC algorithm will compensate for missed meal boluses and 
mitigate prolonged hyperglycemia. The MPC algorithm uses a control-to-target strategy 
that attempts to achieve and maintain a set target glucose value, thereby reducing the 
duration of prolonged hyperglycemia and hypoglycemia. The MPC algorithm resides on 
the Pod (Pump) component of the Omnipod® Horizon System (similar to the DASH ACE 
pump cleared in K191679, as described further below). 
 
The Omnipod Horizon™ app will be the primary user interface and will be used to start 
and stop a Pod, program basal and bolus calculator settings for Manual Mode as well 
as program settings specific for Automated Mode (hybrid closed-loop).  
 
Manual Mode 
 
In Manual Mode, the Horizon™ System will function equivalently to the Omnipod® 
DASH System, which was first cleared under K180045, most recently under K191679. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 18 
This includes delivering insulin at programmed basal rates and bolus amounts with the 
option to set temporary basal profiles. The Omnipod Horizon™ Controller will also have 
the ability to function as a sensor augmented pump in Manual Mode, using sensor 
glucose data provided by the iCGM to populate the bolus calculator. 
 
Automated Mode 
 
In Automated Mode, the system will support the use of multiple target glucose values, 
currently intended to be 110-150 mg/dL at commercialization, in 10 mg/dL increments. 
The experience for the user will reflect current setup flows whereby the health care 
provider assists the user to program basal rates, glucose targets and bolus calculator 
settings. These in turn will inform the MPC algorithm for insulin dosing parameters. The 
insulin dosing parameters will be adapted over time based on the total daily insulin 
(TDI) delivered during each Pod use. A temporary hypoglycemia protection mode (Hypo 
Protect) may be implemented by the user for various time durations during Automated 
Mode. With Hypo Protect, the algorithm reduces insulin delivery and is intended for use 
over temporary durations when insulin sensitivity is expected to be higher, such as 
during exercise. 
 
The Omnipod Horizon™ System will include two apps on a locked-down smartphone 
(the Samsung J3), referred to as Personal Diabetes Manager (PDM): the Horizon App 
and the Dexcom App. The Horizon App, which will have a similar interface to the 
cleared Omnipod® DASH System (K191679), will allow the use of large text, graphics, 
and on-screen instructions to prompt the user through set-up processes. It will also be 
used to program the user’s custom basal insulin delivery profile, check the Pod status, 
initiate bolus doses of insulin, make changes to a patient’s insulin delivery profile, 
handle system alerts and alarms, and enter Automated Mode.  
 
The Dexcom App interface is identical to the current app of the interoperable Dexcom 
G6 Continuous Glucose Monitoring System (K191450) and will provide CGM data, 
alerts, and alarms to the user.  
 
The Horizon App and Dexcom App will not directly communicate with one another. 
Instead, the iCGM transmitter will communicate EGV (estimated glucose values) 
directly to the Pod. The Dexcom transmitter number must be entered into the Horizon 
App, and this information is sent to the Pod to allow transmission of EGV. The Pod will 
pair directly to the transmitter to receive EGV for the algorithm and also sends the EGV 
back to the Horizon App as shown in Figure 1. 
 
The Omnipod Horizon™ Controller provides the ability to calculate a suggested bolus 
dose through the use of the bolus calculator. The bolus calculator will have the option 
for user-selected population of the EGV, which is communicated to the app via the Pod. 
This suggested bolus calculation feature is provided as a convenience to the user to aid 
in determining the suggested bolus dose based on ingested carbohydrates, most recent 
sensor glucose reading (or blood glucose reading if using fingerstick), programmable 
correction factor, insulin to carbohydrate ratio, target glucose value and insulin on board 
(IOB). IOB is calculated by the algorithm taking into account any manual bolus and 
insulin delivered by the algorithm. 
 
As with the cleared Omnipod® DASH System, Insulet will utilize a proprietary encrypted 
security stack embedded within the Bluetooth Low Energy (BLE) communication 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 19 
between the Horizon app and Pod. The communication to the iCGM will use Dexcom’s 
communication protocol. The proprietary security stack increases the resilience of the 
device and improves the ability of the system to be protected in the event of future 
identification of vulnerabilities in standard communication protocols. 
 
2.1.2. Omnipod Horizon™ ACE Pump 
The Pod component of the Omnipod Horizon™ System is similar to the Omnipod® 
DASH ACE Pump cleared under K191679. Compared to the DASH ACE Pump 
(K191679), the Horizon™ ACE Pump (Pod) has additional software to optimize 
communication to accept inputs from the iCGM (initially the Dexcom G6) and the 
Horizon™ Controller.  The insulin delivery mechanism and the patient and fluid 
contacting components are identical to the DASH Pod. 
 
The Pod is a lightweight, self-adhesive device that the user fills with U-100 rapid-acting 
insulin and wears directly on their body. The Pod delivers insulin into the user’s body 
through a small flexible tube, called a cannula, based on the commands from the 
compatible controller. In the Omnipod Horizon™ System, the Pod will house the MPC 
algorithm and communicate directly with the iCGM and the Horizon App. The algorithm 
commands the Pod’s insulin delivery in the form of micro-boluses based on predicted 
glucose values. Figure 2 below is a representation of the Pod.  
 
 
Figure 2:  The Pod of the Omnipod Horizon ACE pump 
 
  
2.1.3. iCGM 
The third component of the Omnipod Horizon™ System is the iCGM. The Omnipod 
Horizon™ System will be interoperable with a compatible iCGM, currently the Dexcom 
G6 Continuous Glucose Monitoring System (K191450). The Omnipod Horizon™ Pod 
will communicate with the Dexcom G6 via Bluetooth Low Energy (BLE). Glucose values 
from the Dexcom transmitter will be sent to the MPC algorithm residing on the Pod and 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 20 
used in insulin dosing adjustments. The glucose values from the Dexcom transmitter 
will be sent independently to the Dexcom App on the controller.  
3 
HORIZON™ DATA PORTAL 
Data are securely uploaded from the PDM to Insulet Cloud by cellular connection. Data 
are then transferred from Insulet Cloud to the Horizon Data Portal (HDP), which is a 
platform for data review and management. The HDP runs on an Amazon-based web 
server. The HDP will provide insights including but not limited to: time in range, time at 
each target BG, automated/manual mode comparisons, and time spent in each mode.  
Alerts and alarms triggered by the PDM will also be logged in the portal.  
 
Investigators will have access to all uploaded data and be able to view historical trends. 
During the prepivotal study, the system will provide a means for investigators to monitor 
live updates of CGM and insulin delivery as well as system alerts and alarms.           
 
 
3.1 Remote Monitoring 
Subjects will be monitored remotely via the HDP alert system during the prepivotal 
hybrid closed-loop phase to allow for real-time assessment of safety.  
 
Investigators will be alerted via text message to prespecified alerts including: 
 
• 
No data alert for 60 minutes 
• 
Sensor glucose <55 mg/dL  
• 
Sensor glucose <70 mg/dL for 20 minutes 
• 
Sensor glucose >300 mg/dL for 1 hour 
Contact information for site staff will be programmed into the HDP. In the event of 
an alert, site staff will receive a text message describing the specific alert type and 
will contact subjects for follow-up.      
   
4 
RESULTS FROM FEASIBILITY STUDIES 
The Omnipod Horizon™ System has been tested in 194 subjects across IDE G160169, 
G170012, G170143 yielding approximately 13,000 subject hours of hybrid closed-loop 
control. The study results were presented in part at ATTD 2017, 2018, ADA 2017, 2018, 
and 2019, and have also been published in Diabetes Technology and Therapeutics 13, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 23,29. 
5 
STUDY SUMMARY 
5.1 Study Purpose 
The purpose of this study is to assess the safety and effectiveness of the 
Omnipod Horizon™ System in patients with type 1 diabetes.     

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 21 
5.2 Study Design 
This is a single-arm, multi-center, prospective clinical study. Up to 48 subjects aged 6-
70 years with type 1 diabetes will be enrolled in the study in order to obtain a minimum 
of 36 evaluable subjects, 18 evaluable subjects in each age cohort (Table 1:  Cohorts). 
Subjects will be enrolled across 6-8 clinical study sites. Subjects who have previously 
participated during the feasibility studies may be enrolled in the prepivotal study and will 
be assigned a new subject identification number.  
The study schedule consists of the following two phases: 
1) 14-day outpatient standard therapy phase followed by; 
2) 14-day hybrid closed-loop phase 
 
Cohorts are defined as shown in Table 1: 
Table 1:  Cohorts 
 
 
 
 
 
 
 
 
 
 
Following subject screening, enrollment, and device training, subjects will commence 
the outpatient standard therapy phase of the study.  
 
Current Dexcom G6 CGM users may provide data from a 14-day period within the last 
30-days. The CGM data meeting the minimum criteria must be the most recent data 
from the last 30-days. For non-G6 users, subjects will wear a study CGM, in blinded 
mode, to record glucose measurements over 14-days while subjects manage their 
diabetes at home per their usual routine while wearing a study CGM while remaining on 
their current MDI or pump therapy, and sensor, if applicable, for 14-days.   
 
After completion of the standard therapy phase, subjects will be trained on the system 
and transition to the hybrid closed-loop phase initiating treatment with the Omnipod 
Horizon™ System.   
 
Clinical site staff will receive alerts through a remote monitoring system during the 
hybrid closed-loop phase. 
 
For the hybrid closed-loop phase, subjects will be divided into two groups: 
 
 
 
 
Cohort  
Age Range 
N (minimum) 
Adults 
14-70 years 
18 
Children 
6-13.9 years 
18 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 22 
Group 1: 
 
1. N=16 subjects aged 6-70 years will participate in the hybrid closed-loop phase 
for the first 2-days while in a supervised hotel/rental house environment and 
then transition to 12-day outpatient environment 
o N=8 subjects aged 6-13.9 years 
o N=8 subjects aged 14-70 years 
 
Group 2: 
 
2. N=20 subjects aged 6-70 years will participate in the hybrid closed-loop phase in 
a remotely monitored 14-day outpatient environment 
o N=10 subjects aged 6-13.9 years 
o N=10 subjects aged 14-70 years 
 
The first group of subjects (n=16) will commence the hybrid closed-loop phase in the 
hotel setting. On study day 3, subjects will transition to the outpatient setting for the 
remaining 12-days. After all subjects from the first group have completed the 2-day 
hotel phase, the second group of subjects may commence hybrid closed-loop. The 
second group of subjects (n=20) will use hybrid closed-loop in the outpatient setting for 
14-days.  It is anticipated that Group 1 will solely consist of existing Dexcom G6 users 
(those who were using the Dexcom G6 at the time of screening), while Group 2 will 
include some existing Dexcom G6 users and some non-Dexcom G6 users.  Therefore, 
the primary safety and primary effectiveness endpoints will also be presented by 
Dexcom G6 use (users and non-users). 
 
All subjects will participate in target BG challenges during the hybrid closed-loop phase. 
In total, all subjects will complete 14-days of closed-loop control, with approximately 72- 
hours spent at target blood glucose levels set to 130mg/dL, 140mg/dL and 150mg/dL, 
respectively. 
 
After each subject in the prepivotal study has successfully completed 14-days of hybrid-
closed-loop, they may immediately transition to and enroll in the pivotal study bypassing 
standard therapy (Phase 1) and continuing with the pivotal hybrid closed-loop phase 
(Phase 2). Remote monitoring will be discontinued as each subject enrolls in the pivotal 
study. 
 
After 16-subjects from the prepivotal study have completed a minimum of 10-days on 
hybrid-closed-loop, the Data Safety Monitoring Board (DSMB) will convene and if the 
system is determined to be safe, the pivotal study may open enrollment to additional 
subjects for the hybrid closed-loop phase (Phase 2).    
 
The standard therapy phase (Phase 1) of the pivotal study may commence in parallel to 
the prepivotal study. Figure 3 is a representation of the prepivotal transition into pivotal. 
  
 
 

 
 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 23 
 
Figure 3:  Horizon Prepivotal Transition into Pivotal

 
 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 24 
Table 2:  Schedule of Assessments 
Assessment Schedule 
Screening 
ST1 
ST2 
Hybrid Closed-Loop (HCL) 
EWa 
  
Phase 1 
Phase 2 
  
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
UVb 
  
Study Day/Visit Window 
-30d to   
HCL start 
-14d to 
HCL 
start 
-1d to 
HCL 
start 
1 
2 
3 
4 
+1d 
7 
±1d 
10 
±1d 
14 
+2d 
N/A 
  
Group 1i: 
2-day Hotel + 
12-days Outpatient 
Hotel (H), Telephone (T) or Office (O) Visit 
O 
O 
O 
H 
H 
H 
T/Of 
T/Of 
T/Of 
T/Of 
T/Of 
O 
Group 2i: 
14-days Outpatient 
Hotel (H), Telephone (T) or Office (O) Visit 
O 
O 
O 
O 
T/Of 
T/Of 
T/Of 
T/Of 
T/Of 
T/Of 
T/Of 
O 
Laboratory Assessments 
A1C 
X 
  
  
  
  
  
  
  
  
  
  
  
TSH 
X 
  
  
  
  
  
  
  
  
  
  
  
Creatinine Level  
X 
  
  
  
  
  
  
  
  
  
  
  
Pregnancy Test 
X 
  
  
X 
  
  
  
  
  
  
  
  
Clinical Assessments 
Informed Consent 
X 
  
  
  
  
  
  
  
  
  
  
  
Confirm Eligibility 
X 
  
  
  
  
  
  
  
  
  
  
  
Medical History (including 
demographics) 
X 
  
  
  
  
  
  
  
  
  
  
  
Concomitant medications 
X 
Xe 
  
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Average total daily insulin (~ 7 days) 
 
X 
  
X 
  
  
  
  
  
  
  
  
Average total basal insulin (~ 7 days) 
 
X 
  
X 
  
  
  
  
  
  
  
  
Average total bolus insulin (~ 7 days) 
 
X 
  
X 
  
  
  
  
  
  
  
  
Pump settings/MDI dosing 
  
X 
  
X 
  
  
  
  
  
  
  
  

 
 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 25 
Assessment Schedule 
Screening 
ST1 
ST2 
Hybrid Closed-Loop (HCL) 
EWa 
  
Phase 1 
Phase 2 
  
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
UVb 
  
Study Day/Visit Window 
-30d to   
HCL start 
-14d to 
HCL 
start 
-1d to 
HCL 
start 
1 
2 
3 
4 
+1d 
7 
±1d 
10 
±1d 
14 
+2d 
N/A 
  
Height 
X 
  
  
  
  
  
  
  
  
X 
  
X 
Weight 
X 
  
  
  
  
  
  
  
  
X 
  
X 
Vital signs 
X 
  
  
  
  
  
  
  
  
X 
X 
X 
Electrocardiogramc (if applicable) 
X 
  
  
  
  
  
  
  
  
  
  
  
Adverse events 
  
  
  
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Questionnaires 
See Table 3 for specific questionnaires 
X 
X  
  
  
  
  
  
  
  
X 
  
X 
Study Devices 
Training on Glucagon administration 
and information on treatment of 
hypo/hyperglycemia 
  
X 
  
  
  
  
  
  
  
  
  
  
Remote monitoring 
initiation/discontinuation 
  
  
  
X 
  
  
  
  
  
X 
  
X 
Study device training 
  
Xg 
  
Xh 
  
  
  
  
  
  
  
  
Dispense/Return 
BG/Ketone meter, and CGM 
  
X 
  
  
  
  
  
  
  
Xd 
  
X 
QC testing of BG/Ketone meter by site 
  
X 
  
  
  
  
  
  
  
  
  
  
CGM sensor placement (as needed 
throughout) 
  
X 
  
  
  
  
  
  
  
  
  
  
Assess CGM usage and data criteria 
has been met 
Xj 
  
X 
  
  
  
  
  
  
  
  
  
Dispense/Return Horizon System 
  
  
  
X 
  
  
  
  
  
Xd 
  
X 
Complaints/device deficiencies 
  
  
  
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Xe 
Device uploads/Data review 
  
  
  
X 
X 
X 
X 
X 
X 
X 
X 
X 

 
 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 26 
Abbreviations:  S=Screening; ST1=Standard Therapy Day One; ST2=Standard Therapy Day Two; HCL=Hybrid Closed-loop; EW=Early 
Withdrawal; QC=Quality Control Testing; Hotel/Rental House=HRH; UV=Unscheduled Visit 
aEarly withdrawal visit will only be conducted for any subjects that started but did not complete the full study to include standard therapy 
and the hybrid closed-loop phase.   
bUnscheduled visits will serve as extra study visits, if needed 
cElectrocardiogram required for subjects >50 years old or with diabetes duration >20 years 
dCollect only if subject is not extending their participation into the pivotal study 
eDocumentation only applicable if there are changes from previous assessment 
fVisits identified as "T/O" can either be conducted in person at the clinical site or over the telephone. Visits identified as "O" can only be 
conducted in person at the clinical site 
gStudy device training for the CGM, blood glucose and ketone meters 
hStudy device training for the Omnipod Horizon™ System 
iSubjects deemed exempt from wearing the study CGM for 14-days will be eligible to immediately commence the hybrid closed-loop phase 
and may skip visit ST2 
jAssessment of CGM criteria during screening applies to current Dexcom G6 users only 
 
 
 

 
 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 27 
 
Table 3:  Questionnaires 
Visit    
Age Groups 
Adult 
Teen 
(ages 12-18) 
Caregiver-Teen 
(ages 12-18) 
Pediatric 
(ages 8-11.9) 
Caregiver-Pediatric 
(ages 6-11.9) 
Screening 
Clarke 
Clarke 
n/a 
n/a 
Clarke 
Visit 2 
WHO-5 
EQ-5D 
T1DDS 
DTSQs 
Hypoglycemia 
Confidence Scale 
HABS 
PSQI 
IDSS (T1) 
SUS 
WHO-5 
EQ-5D 
PAID-Teen 
Hypoglycemia 
Confidence Scale 
PSQI 
SUS 
WHO-5 
P-PAID-Teen 
Hypoglycemia 
Confidence Scale 
PSQI 
DTSQs 
IDSS (T1) 
EQ-5D-Y 
PAID-Child 
WHO-5 
P-PAID-Child 
Hypoglycemia 
Confidence Scale 
PSQI 
DTSQs 
IDSS (T1) 
SUS 
Final 
Visit/Early 
Withdrawal 
WHO-5 
EQ-5D 
T1DDS 
DTSQc 
Hypoglycemia 
Confidence Scale 
HABS 
PSQI 
IDSS (T1) 
SUS 
INSPIRE-Adult 
Clarke 
HF Questionnaire 
WHO-5 
EQ-5D 
PAID-Teen 
Hypoglycemia 
Confidence Scale 
PSQI 
SUS 
INSPIRE-Youth 
Clarke 
HF Questionnaire 
WHO-5 
P-PAID-Teen 
Hypoglycemia 
Confidence Scale 
PSQI 
DTSQc 
IDSS (T1) 
INSPIRE-Parent 
EQ-5D-Y 
PAID-Child 
INSPIRE-Youth 
WHO-5 
P-PAID-Child 
Hypoglycemia 
Confidence Scale 
PSQI 
DTSQc 
IDSS (T1) 
SUS 
INSPIRE-Parent 
Clarke 
HF Questionnaire 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 28 
6 
OBJECTIVES AND ENDPOINTS 
6.1 Safety Objective 
The safety objective of this study is to evaluate the safety of the Omnipod 
Horizon™ System in patients with type 1 diabetes. 
6.1.1 Primary Safety Endpoint 
Proportion of subjects with serious device-related adverse events. 
 
6.1.2 Secondary Safety Endpoints 
• 
Proportion of subjects with severe hypoglycemia during hybrid closed-
loop 
• 
Proportion of subjects with diabetic ketoacidosis (DKA) during hybrid 
closed-loop 
 
 
6.2 Primary Effectiveness Objective 
The primary effectiveness objective of this study is to evaluate the effectiveness of 
the Omnipod Horizon™ System. 
 
6.2.1 Primary Effectiveness Endpoint 
Percentage of time in range (70-180 mg/dL) during hybrid closed-loop compared 
to standard therapy for: 
 
• 
Target BG challenge days (approximately hybrid closed-loop days 1-9) 
• 
Non-challenge days (approximately hybrid closed-loop days 10-14) 
• 
Overall (hybrid closed-loop days 1-14) 
 
6.3 Secondary Effectiveness Objective 
To evaluate additional glycemic measures of effectiveness of the Omnipod 
Horizon™ System in patients with type 1 diabetes.  
6.3.1 Secondary Effectiveness Endpoints 
The secondary objective will be evaluated using the following per subject 
endpoints:   
• 
Glucose metrics from system CGM during the hybrid closed-loop phase will 
be compared to the standard therapy phase during the day, overnight, and 
overall: 
 
• 
Mean glucose 
• 
% of time in range 70-180 mg/dL 
• 
% of time in range 70-140 mg/dL 
• 
% of time > 180 mg/dL 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 29 
• 
% of time ≥ 250 mg/dL 
• 
% of time ≥ 300 mg/dL 
• 
% of time < 70 mg/dL 
• 
% of time < 54 mg/dL 
• 
Standard deviation 
• 
Coefficient of variation 
 
• 
GMI based on overall mean glucose 
• 
Percentage of time in hybrid closed-loop as proportion of overall device 
usage time 
• 
Insulin requirements during the hybrid closed-loop phase will be compared to 
the standard therapy phase: 
 
• 
Total daily insulin (TDI) (units, units/kg) 
• 
Total daily basal insulin (units, units/kg) 
• 
Total daily bolus insulin (units, units/kg) 
 
 
7 
SCREENING AND ELIGIBILITY 
Potential subjects for this study will include individuals who have been diagnosed with 
type 1 diabetes for at least 6 months and are appropriate for pump therapy per 
investigator’s assessment. Potential subjects will be selected at each clinical study site 
and screened accordingly. Clinical study sites will be advised to: 
• 
Recruit subjects using insulin aspart, lispro, and glulisine also known as 
Humalog, Novolog, Admelog, and Apidra 
• 
Recruit at least 20% of subjects using MDI 
Every effort will be made to establish eligibility of the patient prior to enrollment. Only 
patients who appear to meet all eligibility criteria will be enrolled in the study. Subject 
eligibility will be confirmed by study staff during a screening visit at the clinical site. 
Blood draws will be collected as required to demonstrate study eligibility as noted 
below. Laboratory results within the last 6 months, with the exception of A1C, may also 
be used if available.   
 
Subjects that have participated in the prepivotal study may be eligible to extend their 
participation into the pivotal study. 
7.1 Visit 1 
Visit 1 will be conducted in person at the clinical study site. This visit will assess 
eligibility and will include: 
 
• 
Signing of informed consent/assent 
• 
Review of inclusion/exclusion criteria 
• 
Screening assessments performed following Table 2:  Schedule of 
Assessments 
• 
Enrollment 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 30 
 
Informed Consent/Assent 
 
Subjects who appear to meet the eligibility criteria will be asked to sign an 
Informed Consent Form (ICF) approved by each respective Institutional Review 
Board (IRB) for participation in the study. A parent/guardian must sign the ICF for 
subjects <18 years of age. Assent will also be obtained from subjects aged <18 
years per State requirements. Failure to provide informed consent/assent will 
render the subject ineligible for the study. 
Subjects must also have a signed HIPAA (Health Insurance Portability and 
Accountability Act) release of protected health information (PHI). The release may 
be a stand-alone document or part of the informed consent. 
After informed consent/assent is obtained, a subject identification number will be 
issued to uniquely identify each subject. The unique identifier will be used to 
identify the subject throughout the study and will be used for all source documents 
and electronic Case Report Forms (eCRFs). Subjects will retain the same subject 
identification number if they continue in the pivotal study.  
Inclusion Criteria  
Subjects must meet all of the following criteria in order to be enrolled in the study: 
1. Age at time of consent 6-70 years 
2. Subjects aged < 18 years must be living with parent/legal guardian 
3. Diagnosed with type 1 diabetes for at least 6 months. Diagnosis is based on 
investigator’s clinical judgment 
4. Deemed appropriate for pump therapy per investigators assessment taking 
into account previous history of severe hypoglycemic and hyperglycemic 
events, and other comorbidities 
5. Investigator has confidence that the subject can successfully operate all 
study devices and is capable of adhering to the protocol 
6. Willing to use only Humalog, Novolog, Admelog or Apidra during the study 
7. Must be willing to set target glucose between 130-150 mg/dL each for 
approximately 72-hours on predefined days during the hybrid closed-loop 
phase 
8. Must be willing to extend their participation into the pivotal study if they 
continue to meet the protocol criteria 
9. Willing to wear the system continuously throughout the study 
10. A1C <10% at screening visit 
11. Must be willing to use the Dexcom App on the Omnipod Horizon PDM as the 
sole source of Dexcom data (with the exception of the Dexcom Follow App) 
during the hybrid closed-loop phase 
12. Subjects scoring ≥ 4 on the Clarke Questionnaire must agree to have an 
overnight companion, defined as someone who resides in the same home or 
building as the study subject and who can be available overnight 
13. Able to read and speak English fluently 
14. Subject must be in an AT&T covered area 
15. Willing and able to sign the Informed Consent Form (ICF) and/or has a 
parent/guardian willing and able to sign the ICF. Assent will be obtained from 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 31 
subjects aged < 18 years per State requirements. 
Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from the study: 
1. A medical condition, which in the opinion of the investigator, would put the 
subject at an unacceptable safety risk 
2. History of severe hypoglycemia (as defined in Section 11.3.3) in the past 6 
months 
3. History of Diabetic Ketoacidosis (DKA) (as defined in Section 11.3.4) in the 
past 6 months, unrelated to an intercurrent illness, infusion set failure or 
initial diagnosis 
4. Diagnosed with sickle cell disease 
5. Diagnosed with hemophilia or any other bleeding disorders 
6. Plans to receive blood transfusion over the course of the study 
7. Currently diagnosed with anorexia nervosa or bulimia 
8. Acute or chronic kidney disease (e.g. estimated GFR < 45) or currently on 
hemodialysis 
9. History of adrenal insufficiency 
10. Has taken oral or injectable steroids within the past 8 weeks or plans to take 
oral or injectable steroids during the course of the study 
11. Unable to tolerate adhesive tape or has any unresolved skin condition in the 
area of sensor or pump placement 
12. Use of insulin other than U-100 insulin intended for use in the pump  
13. Use of non-insulin anti-diabetic medication other than metformin (e.g. GLP1 
agonist, SGLT2 inhibitor, DPP-4 inhibitor, pramlintide) 
14. Current or known history of coronary artery disease that is not stable with 
medical management, including unstable angina, or angina that prevents 
moderate exercise despite medical management, or a history of myocardial 
infarction, percutaneous coronary intervention, or coronary artery bypass 
grafting within the previous 12 months.  
15. For subjects > 50 years old or with diabetes duration > 20 years, abnormal 
electrocardiogram consistent with increased risk of arrhythmia, ischemia, or 
prolonged QTc interval (> 450 ms)  
16. Thyroid Stimulating Hormone (TSH) is outside of normal range with 
clinical signs of hypothyroidism or hyperthyroidism 
17. Pregnant or lactating, or is a woman of childbearing potential and not on 
acceptable form of birth control (acceptable includes abstinence, condoms, 
oral/injectable contraceptives, IUD or implant) 
18. Participation in another clinical study using an investigational drug or device 
within the preceding 30-days or intends to participate during the study period   
19. Unable to follow clinical protocol for the duration of the study or is otherwise 
deemed unacceptable to participate in the study per the investigator’s clinical 
judgment 
Screening Assessments 
Subjects who have signed the informed consent and appear to meet the eligibility 
criteria will continue to the screening assessments which will be performed at the 
clinical study site.  

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 32 
Screening assessments must be completed within 30-days prior to the start date 
of the hybrid closed-loop phase (assessments do not need to be completed on the 
same day) and include the following: 
• 
Medical history (including prior and current medical conditions and surgical 
history) 
• 
Demographics (age, gender, race) 
• 
A1C*  
• 
Thyroid Stimulating Hormone (TSH) level (local laboratory) 
• 
Creatinine level (local laboratory) 
• 
Pregnancy test for women of childbearing potential 
• 
Review of concomitant medications 
• 
Height 
• 
Weight 
• 
Assessment of vital signs 
• 
Electrocardiogram (if applicable, see exclusion criteria 15) 
• 
Questionnaire (Table 3:  Questionnaires): 
o Clarke  
▪ 
Used to assess impaired awareness of hypoglycemia 
• 
For Dexcom G6 users, assessment of whether subjects have met the CGM 
usage and data criteria to participate in an abbreviated standard therapy 
phase (Visit 2 only) per Table 2:  Schedule of Assessments 
o At least 80% CGM use (11.2-days) during any consecutive 14-days in 
the past 30-days and 
o ≥ 2,016 CGM values during the 14-days 
 
*Clinical sites will send the blood specimens for A1C to a NGSP (National 
Glycohemoglobin Standardization Program) certified central laboratory. A point of 
care (POC) A1C may be used to determine eligibility.  
The Clarke Questionnaire will be administered during the screening visit. Subjects 
scoring ≥ 4 on the Clarke Questionnaire will require an overnight companion 
during the hybrid closed-loop phase A companion is defined as someone who 
resides in the same home or building as the study subject and who can be 
available overnight. 
Enrollment 
Subjects who meet all eligibility criteria and have completed all screening 
assessments will continue to enrollment. A subject is enrolled in the study upon 
placement of the first study CGM. Subjects that do not meet the eligibility criteria 
will not continue in the study and will be considered screen failures.  
If for any reason a subject is no longer eligible for the study after the standard 
therapy phase has commenced but prior to the commencement of the hybrid 
closed-loop phase, the subject will not continue in the prepivotal study. No 
additional study assessments will be required. The reason for study exit will be 
clearly documented. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 33 
8 
STANDARD THERAPY - PHASE 1 
The standard therapy phase will commence after all standard therapy assessments are 
completed per Visit 2 – see Table 2:  Schedule of Assessments.  
During the standard therapy phase, subjects will be asked to perform the following: 
• 
Manage their diabetes at home per their usual routine 
• 
Administer meal boluses per their usual dosing routine 
• 
Change their sensor if a sensor fails, or as needed 
• 
Calibrate their CGM, if required, per the manufacturer’s instructions   
• 
Monitor their capillary blood glucose (BG) per usual routine 
• 
Give meal boluses. The timing of the bolus delivery will be per each subject’s 
typical dosing routine. 
Extending standard therapy past 14-days will not constitute a protocol deviation unless 
standard therapy extends past 30-days. If subjects extend beyond the 14-days, the 
most recent 14-days of data will be used in the endpoint analysis if the data meets the 
criteria defined for CGM use and data availability. If a subject enrolls into the pivotal 
study, data collected in the standard therapy phase will be used in the endpoint 
analyses for the pivotal study as the subject will not be required to repeat the standard 
therapy phase as part of the pivotal study.    
The standard therapy phase will be customized depending on the following subject 
profile: 
 
• 
Current Dexcom G6 users  
• 
Non-G6 users 
• 
Pump Naïve users 
 
Current Dexcom G6 Users 
 
Current Dexcom G6 users will be required to participate in the assessments required as 
part of standard therapy but may be exempt from wearing the study CGM for 14-days if 
the following criteria are met: 
 
• 
Willing to provide 14-days of CGM data from the past 30-days 
• 
Meet the success criteria of 80% CGM use during any consecutive 14-days in the 
past 30-days 
• 
Must have ≥ 2,016 CGM values during the 14-days 
 
If exemption criteria are not met, subjects may choose to continue to collect data until 
they meet the criteria or will be required to participate in the entire 14-day standard 
therapy phase consistent with the requirements for non-G6 users. 
 
Subjects deemed exempt from wearing the study CGM for 14-days will be eligible to 
immediately commence the hybrid closed-loop phase.   
 
Non-G6 Users 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 34 
 
All non-G6 users will be required to participate in the entire 14-day standard therapy 
phase. At the commencement of the standard therapy phase, subjects will be 
dispensed a CGM receiver that will be blinded and all user settable CGM alerts will be 
turned off. The device will record continuous glucose information over the 14-day 
period.   
 
Pump Naïve Users 
Subjects who are naïve to pump therapy will have the opportunity to participate in a 
saline trial during the standard therapy phase. A saline trial consists of wearing a 
cleared Omnipod® DASH System with the Pod filled with saline to simulate pump 
therapy. This would enable subjects to familiarize themselves with the basic concepts of 
basal and bolus insulin delivery as well as provide the experience of wearing an on-
body device prior to their participation in the hybrid closed-loop phase, if they choose to 
do so. This is optional and not required.  
8.1 Visit 2 
Visit 2 represents the commencement of the standard therapy phase. All 
scheduled assessments will be performed according to Table 2:  Schedule of 
Assessments. This visit will include: 
• 
Review of concomitant medications 
• 
Average total daily insulin (approximately over the past 7 days) 
• 
Average total daily basal insulin (approximately over the past 7 days) 
• 
Average total daily bolus insulin (approximately over the past 7 days) 
• 
Review pump settings/MDI dosing 
• 
Completion of questionnaires (see Table 3:  Questionnaires for specific 
requirements by age group): 
• 
WHO-5 
o Used to measure current mental well-being 
• 
EQ-5D 
o Used to measure quality of life 
• 
T1DDS 
o Used to measure four critical dimensions of distress 
• 
DTSQs  
o Used to measure satisfaction with diabetes treatment regimens 
• 
Hypoglycemia Confidence Scale 
o Used to measure hypoglycemia unawareness, hypoglycemia 
frequency, severity and impact 
• 
HABS 
o Used to measure critical dimensions of hypoglycemia related 
concerns and confidence 
• 
PSQI 
o Used to measure sleep disturbance and usual sleep habits 
• 
IDSS (T1) 
o Used to measure patient satisfaction with their devices and impact 
on quality of life 
• 
SUS 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 35 
o Used to measure usability of a system 
• 
PAID-(Teen, Child) 
o Measures diabetes-related burden 
• 
Training on Glucagon administration and information on treatment of 
hypo/hyperglycemia   
• 
All subjects are required to have access to glucagon and receive 
training on how to deliver the medication 
• 
Study device training per manufacturer’s instructions (CGM - blinded, BG, 
and ketone meters) 
• 
Dispensing of CGM (blinded for non-G6 users), BG, and ketone meter 
• 
QC testing of BG and ketone meter 
• 
Must pass as least one level of quality control testing prior to 
dispensing 
• 
CGM sensor placement (if applicable)   
• 
Approved anatomical locations for CGM sensor placement will be 
reinforced as well as the importance of using approved locations 
During this visit, subjects will be dispensed the following supplies: 
• 
Dexcom transmitter 
• 
Dexcom receiver 
• 
Dexcom sensors 
• 
Contour® Next One blood glucose meter 
• 
Contour® Next One blood glucose meter test strips 
• 
Contour® Next One blood glucose meter control solution 
• 
Lancets 
• 
Precision Xtra blood ketone meter 
• 
Precision Xtra blood ketone meter test strips 
• 
Precision Xtra blood ketone meter control solution 
 
Subjects will be provided, by the site, information regarding treatment of 
hypoglycemia and hyperglycemia including sick day management and emergency 
management of severe hypoglycemia and diabetic ketoacidosis. Subjects will be 
given contact information for study personnel and product support.     
If a subject is on MDI, the investigator will advise the subject on the treatment 
regimen to reduce insulin depending on the insulin action profile of injected doses 
prior to the commencement of the hybrid closed-loop phase. MDI subjects will be 
required to keep a log to record daily doses of insulin during the standard therapy 
phase. 
8.2 Visit 3 
Visit 3 will be conducted in person at the clinical study site one (1) day prior to the 
start of the hybrid closed-loop phase. All scheduled assessments will be 
performed according to Table 2:  Schedule of Assessments. This visit will include 
assessment of whether subjects have met the CGM usage and data criteria. 
 
Prior to the commencement of the hybrid closed-loop phase, subjects must meet 
the following criteria: 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 36 
 
o At least 80% CGM use (11.2-days) during any consecutive 14-days in the 
past 30-days and 
o ≥ 2,016 CGM values during the 14-days 
If the CGM criteria is not met, the standard therapy phase may be extended, per 
investigator discretion, or the subject may be withdrawn from the study.  At the 
conclusion of the standard therapy phase, if the investigator determines that there have 
been no safety concerns, the subject will continue to the hybrid closed-loop phase. If 
the investigator determines that it is unsafe for the subject to continue into the hybrid 
closed-loop phase, the subject will not be allowed to continue in the second phase of 
the study, and the reason for study exit will be documented. 
 
9 
HYBRID CLOSED-LOOP - PHASE 2 
The hybrid closed-loop phase will commence at Visit 4 upon the conclusion of the 
standard therapy phase and after all assessments are performed according to Table 2:  
Schedule of Assessments.   
During the hybrid closed-loop phase, subjects will be asked to do the following: 
• 
Adjust pump and CGM parameters to optimize their insulin therapy in 
collaboration with the recommendations from the clinical study staff 
• 
Follow their pre-exercise management such as insulin reduction for meal 
boluses, consumption of snacks, or adjusting their insulin delivery settings 
• 
Treat themselves per their usual routine if they become hypoglycemic or 
hyperglycemic or have symptoms of either at any time during the study 
• 
Consume meals and snacks of their own choosing. Subjects will be encouraged 
to estimate the grams of carbohydrates for each meal or snack per their usual 
routine. The estimate should be entered into the meal bolus calculator. 
• 
Administer meal boluses per their usual dosing routine 
• 
Participate in target BG challenges as specified 
• 
Change their CGM per manufacturer’s instructions or sooner if necessary 
• 
Change the Pod at least once every 72 hours 
• 
Complete questionnaires (Table 3:  Questionnaires) 
 
Subjects will have scheduled follow-up visits according to Table 2:  Schedule of 
Assessments and complete questionnaires according to Table 3:  Questionnaires. Visits 
will be conducted either in the hotel/rental house environment, in person at the clinical 
study site or over the telephone. Subjects may also choose to use email or text as a 
substitute for their scheduled telephone visit.   
 
The duration of the hybrid closed-loop phase will last 14-days. 
 
9.1 Target BG Challenges 
All subjects will take part in the target blood glucose (BG) challenges (Table 4:  
Target BG Challenges). Following the commencement of the hybrid closed-loop 
phase, subjects will be required to set their target BG to 130 mg/dL for 
approximately 72 hours for days 1-3, 140 mg/dL for days 4-6, and 150 mg/dL for 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 37 
day 7-9 according to Table 4:  Target BG Challenges. Upon completion of the 3 
target BG challenges (130 mg/dL, 140 mg/dL, and 150 mg/dL), subjects may 
choose their desired target BG between 110-150 mg/dL for the remainder of the 5-
days of the hybrid closed-loop phase.  
 
Table 4:  Target BG Challenges 
  
Days 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10-14 
Target 
BG 
130 mg/dL 
140 mg/dL 
150 mg/dL 
110-150 
mg/dL 
 
These settings will be reviewed by clinical staff at scheduled visits and through the 
remote monitoring system to ensure the requirements are met. If the requirements 
have not been met, clinical staff may request the subject adjust their setpoint until 
the requirements are met unless there are safety concerns. 
 
9.2 Hotel/Rental House Environment 
The subset of subjects participating in the hotel/rental house environment will be 
encouraged to eat meals of their own choosing, unrestricted in carbohydrates, and 
to engage in moderate intensity exercise for a minimum of 1 hour per day. 
Moderate intensity exercise is defined using the CDC guidelines12: 
Table 5:  CDC Guidelines12 for Moderate Intensity Exercise 
 
Children and 
Adolescents 
Adults 
Older Adults 
Moderate Intensity 
Activities 
Brisk walking 
Bicycling 
Hiking 
Catching/throwing 
Walking/jogging 2.5 
miles per hour 
Bicycling 
Aerobics 
Walking/hiking 
Jogging 
Bicycling 
Aerobics 
 
9.3 Visit 4 
Visit 4 represents the commencement of the hybrid closed-loop phase. For 
subjects in Group 1, this visit will be conducted at the hotel/rental house. For 
subjects in Group 2 this visit will be conducted at the clinical study site. All 
scheduled assessments will be performed according to Table 2:  Schedule of 
Assessments. This visit will include: 
• 
Pregnancy test for women of childbearing potential 
• 
Review of concomitant medications 
• 
Average total daily insulin (approximately over the past 7 days) 
• 
Average total daily basal insulin (approximately over the past 7 days) 
• 
Average total daily bolus insulin (approximately over the past 7 days) 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 38 
• 
Pump settings/MDI dosing 
• 
Assessment of AEs 
• 
Remote monitoring initiation 
• 
Omnipod Horizon™ System device training conducted by trained clinical 
site staff  
o Subjects will be trained on operating Omnipod Horizon™ in both 
Manual and Automated Modes.  
o This will include first time device set-up with entry of basal profile, bolus 
calculator settings with insulin:carbohydrate ratio, target glucose and 
correction factor.  
o The Pod will be filled with the subject’s own U-100 rapid-acting insulin 
and placed on body. Subjects will also be trained on use of Dexcom G6 
CGM, regardless of previous experience, setting up low (recommended 
to be 70 mg/dL or higher) and high glucose alerts (recommended to be 
300 mg/dL or lower) and entering transmitter serial number into the 
Horizon App.  
o In addition, Omnipod Horizon™ has a novel bolus calculator feature 
that incorporates both the CGM value and trend into the suggested 
bolus amount. In general, if the CGM values are trending up or down, 
the calculator will add or subtract insulin from the suggested bolus 
amount to help keep BGs within target range. 
• 
Dispense Omnipod Horizon™ System 
• 
Complaints/device deficiencies for CGM, BG and ketone meter 
• 
Device uploads for CGM, BG and ketone meter 
• 
Data review by clinician 
• 
Removal of the subject’s personal insulin pump (if applicable) 
o Prior to commencing hybrid closed-loop, the subject’s personal insulin 
pump will be removed, if applicable. Investigators may use the Insulet-
provided Patient Therapy Order Form (PTOF) as a guide to transition 
subjects from MDI to pump therapy (Appendix). 
At the conclusion of the training and completion of assessments, each subject will 
initiate their treatment marking their commencement of the hybrid closed-loop 
phase.  
9.4 Visit 5 
Visit 5 will be conducted in the hotel/rental house for subjects in Group 1, and 
over the telephone for subjects in Group 2. All scheduled assessments will be 
performed according to Table 2:  Schedule of Assessments. This visit will include:  
• 
Review of concomitant medications 
• 
Assessment of AEs since last visit 
• 
Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit 
• 
Device uploads for BG and ketone meter 
• 
Data review by clinician 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 39 
9.5 Visit 6 
Visit 6 will be conducted in the hotel/rental house for subjects in Group 1, and 
over the telephone for subjects in Group 2. All scheduled assessments will be 
performed according to Table 2:  Schedule of Assessments. This visit will include: 
 
• 
Review of concomitant medications 
• 
Assessments of AEs since last visit 
• 
Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit 
• 
Device uploads for BG and ketone meter 
• 
Data review by clinician 
 
Subjects in Group 1 will be discharged home on study day 3 (Visit 6).  
 
During each visit, subjects will be reminded to set the appropriate target BG on the 
appropriate day as applicable.  
 
9.6 Visits 7, 8 and 9 
Visits 7 through Visit 9 will be conducted over the telephone. All scheduled 
assessments will be performed according to Table 2:  Schedule of Assessments. 
These visits will include: 
 
• 
Review of concomitant medications 
• 
Assessment of AEs since last visit 
• 
Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit 
• 
Device uploads for BG and ketone meter (if visit is conducted at the clinical 
study site) 
• 
Data review by clinician 
• 
Ensuring at least 72 hours of data collected at designated target BG levels 
per Table 4 – Target BG Challenges.  
 
During each visit, subjects will be reminded to set the appropriate target BG on the 
appropriate day as applicable.  
 
9.7 Visit 10 (End of Study) 
Visit 10 will be conducted in person at the clinical study site. All scheduled 
assessments will be performed according to Table 2:  Schedule of Assessments. 
If the subject has not experienced any serious adverse events, and continue to 
meet eligibility requirements, the subject will be deemed eligible to participate in 
the pivotal study. This visit will conclude their participation in the prepivotal study. 
This visit will include: 
 
• 
Review of concomitant medications 
• 
Height 
• 
Weight 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 40 
• 
Assessment of vital signs 
• 
Assessment of AEs since last visit 
• 
Completion of questionnaires (see Table 3:  Questionnaires for specific 
requirements by age group) : 
• 
WHO-5 
• 
EQ-5D 
• 
T1DDS 
• 
DTSQc  
• 
Hypoglycemia Confidence Scale 
• 
HABS 
• 
PSQI 
• 
IDSS (T1) 
• 
SUS 
• 
PAID-(Teen, Child) 
• 
INSPIRE-(Adult, Youth, Parent) 
▪ 
Used to measure a caregiver’s experience of the support they 
receive 
• 
Clarke 
• 
Human Factors (HF) Questionnaire 
▪ 
Measures trust in the Horizon™ System 
• 
Discontinuation of remote monitoring 
• 
Return study devices (Omnipod Horizon™ System, CGM, BG and ketone 
meters if not extending into pivotal study) 
• 
Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit 
• 
Device uploads for BG and ketone meter 
• 
Data review by clinician 
 
For subjects not extending their participation into the pivotal study, they will return 
their study devices to the site and their participation in the study will end. 
 
9.8 Unscheduled Visits 
Aside from scheduled visits, subjects may require an unscheduled visit either by 
telephone or in person at the clinical study site. All scheduled assessments will be 
performed according to Table 2:  Schedule of Assessments. This visit will include, 
at a minimum: 
 
• 
Review of concomitant medications 
• 
Assessment of vital signs (if visit is conducted at the clinical study site) 
• 
Assessment of AEs since last visit 
• 
Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• 
Device uploads for BG and ketone meter (if visit is conducted at the clinical 
study site) 
• 
Data review by clinician 
 
Additional assessments may be warranted at the discretion of the investigator. 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 41 
Instructions will be given to subjects on how to contact clinical study staff 24 hours per 
day to report any study related problems. Subjects will be encouraged to call the clinical 
study site at any time with any concerns.  
 
9.9 Early Withdrawal 
Any subject may withdraw early from the study at any time for any reason. Upon 
withdrawal, assessments will be performed following the Table 2:  Schedule of 
Assessments. The investigator may also terminate a subject’s participation in the 
study if it is in the best interest of the subject or if the Sponsor or local regulatory 
agency (e.g., FDA) terminates the study. 
 
The Early Withdrawal visit will include: 
 
• 
Review of concomitant medications 
• 
Height 
• 
Weight 
• 
Assessment of vital signs 
• 
Assessment of AEs since last visit 
• 
Completion of questionnaires (see Table 3:  Questionnaires for specific 
requirements by age group): 
• 
WHO-5 
• 
EQ-5D 
• 
T1DDS 
• 
DTSQc  
• 
Hypoglycemia Confidence Scale 
• 
HABS 
• 
PSQI 
• 
IDSS (T1) 
• 
SUS 
• 
PAID-(Teen, Child) 
• 
INSPIRE-(Adult, Youth, Parent) 
• 
Clarke 
• 
Human Factors (HF) Questionnaire 
• 
Discontinuation of remote monitoring 
• 
Return all study devices  
• 
Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit 
• 
Device uploads for BG and ketone meter 
• 
Data review by clinician 
 
The reasons for withdrawal will be recorded, and the subject’s participation in the 
study will end. 
In the event of a subject’s death during the study, the subject’s participation will be 
considered terminated and the date of death will be used as the date of study exit. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 42 
9.10 Lost to Follow-up 
Every effort will be made to contact a subject in the event of a missed scheduled 
visit. A subject will be considered lost to follow-up if they are inaccessible by two 
or more different methods of contact and fail to show up for two scheduled visits. 
The site will document each attempt made to contact the subject and specify the 
reason for early withdrawal as lost to follow-up. 
 
10  SPONSOR REPRESENTATIVES 
One or more representatives of the Sponsor may be present at the hybrid closed-
loop clinical study site visits under supervision of the investigator. 
 
11 SAFETY 
11.1 Types of Known Risks and Benefits 
There are known risks and benefits. Most of the risks are not unique to the study 
and are typical for patients using insulin pumps, CGM, and BG meters. 
The known risks are as follows: 
• 
Hypoglycemia and/or hyperglycemia as a result of change in diet, activity, 
diabetes management or insulin regimen during the study. 
• 
Hypoglycemia, hyperglycemia, diabetic ketoacidosis, seizure, coma or death 
related to insulin administration, pump use or misuse, or Horizon™ System 
use or misuse. 
• 
Use of the Pod (Omnipod® tubeless, insulin delivery pump) - Because the 
Pod uses only rapid-acting insulin, users are at increased risk for developing 
hyperglycemia if insulin delivery is interrupted. If it is untreated, prolonged 
hyperglycemia can quickly lead to diabetic ketoacidosis (DKA). DKA can 
cause symptoms such as breathing difficulties, shock, coma, or death. 
Further, occlusions can interrupt insulin delivery and lead to hyperglycemia 
or DKA. Other potential risks associated with using the Pod are: 
o Anaphylaxis (allergic shock) 
o Bruising at the Pod site 
o Bleeding at the Pod site 
o Erythema (redness at the Pod site) 
o Excoriation (raw skin at Pod site) 
o Pruritus (itching) 
o Induration (hardening of the skin at the Pod site) 
o Infection (can include heat, redness, swelling, pain, and drainage) 
o Inflammation (redness, swelling) 
o Skin reaction to adhesive at the Pod site 
o Papule (small, solid raised area on the skin similar to a pimple) 
o Pain or discomfort 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 43 
o Ulceration (skin sores) 
o Vesicles (blisters) 
• 
Use of the CGM - risk of bruising, infection, pain and/or bleeding at the site 
of insertion, and skin site reaction to adhesive. 
• 
On rare occasions, the CGM sensor may break and leave a small portion of 
the sensor under the skin that may cause redness, swelling, or pain at the 
insertion site, and may require surgical removal. 
• 
Blood sampling with fingerstick - minor discomfort and risk of infection at site 
of fingerstick. 
There are several potential benefits from this study. The Omnipod Horizon™ 
System is designed to provide automated glucose control. The system is expected 
to reduce hypoglycemia without incurring an unacceptable increase in 
hyperglycemia and mean glucose. The system is also expected to reduce the 
extent and magnitude of hyperglycemia associated with meals. The Omnipod 
Horizon™ System uses a control-to-target strategy that attempts to achieve and 
maintain a set target glucose level. 
11.2 Hypoglycemia/Hyperglycemia 
Subjects will be asked to treat per their usual routine if they suspect either 
hypoglycemia or hyperglycemia, either by confirmation of hypoglycemia with a 
fingerstick BG, symptoms, or perceived risk.  
Subjects will be encouraged to manage their hyperglycemia per their usual 
routine. This includes checking for ketones using the study-approved ketone 
meter and administering a correction bolus if needed. 
In the event of unexplained hyperglycemia, where the CGM is >300mg/dL for 1h 
or >250 mg/dL for 2h, blood glucose (measured with BG meter) and ketones 
should be checked. If BG is ≥300 mg/dL and ketones are >1.0 mmol/L, an 
occlusion or dislodged cannula should be suspected. The Pod should be 
removed, and the subject will be instructed to replace the Pod. Subjects should 
contact the clinical site for further instructions to determine whether an additional 
injection of insulin is required. This prolonged hyperglycemic event, defined as 
meter BG ≥300 mg/dL and ketones >1.0 mmol/L, will be recorded as an adverse 
event and cause may be attributed to suspected occlusion if the cannula is in situ 
or dislodged cannula if it has been pulled out. Pods will be requested to be 
returned to Insulet for analysis. An Adverse Event form will be completed per the 
Reportable Adverse Events section below. 
11.3 Adverse Events 
11.3.1 Definitions 
Adverse Event (AE): is defined as any untoward medical occurrence, unintended 
disease or injury, or any untoward clinical signs (including an abnormal laboratory 
finding) in subjects, users or other persons, whether or not related to the 
investigational medical device. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 44 
NOTE 1: This includes events related to the investigational medical device or the 
comparator.28 
NOTE 2: This definition includes events related to the procedures involved (any 
procedure in the clinical investigation plan).28 
Serious Adverse Event (SAE): Any untoward medical occurrence that: 
o Led to death 
o Led to serious deterioration in the health of the subject, that either 
resulted in: 
▪ 
a life-threatening illness or injury, or 
▪ 
a permanent impairment of a body structure or a body function, or 
▪ 
in-patient or prolonged hospitalization, or 
▪ 
medical or surgical intervention to prevent life-threatening illness 
or injury or permanent impairment to a body structure or a body 
function. 
o Led to fetal distress, fetal death, or a congenital abnormality or birth defect. 
 
NOTE: Planned hospitalization for a pre-existing condition, or a 
procedure required by the clinical investigational plan, without serious 
deterioration in health, is not considered a serious adverse event.28 
Unanticipated Adverse Device Effect (UADE): Any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated 
with, a device, if that effect, problem, or death was not previously identified in 
nature, severity, or degree of incidence in the investigational plan or application 
(including a supplementary plan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of 
participants. 28 
Adverse Device Effect (ADE): An adverse device effect is an adverse event 
related to the use of an investigational medical device. 28  
NOTE 1: This definition includes any adverse event resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or 
operation, or any malfunction of the investigational medical device.28 
NOTE 2: This definition includes any event resulting from user error or from 
intentional misuse of the investigational medical device.28 
Serious Adverse Device Effect (SADE): A serious adverse device effect is 
defined as an adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event. 28 
Device Deficiency (DD): A device deficiency is defined as a device related 
complaint or malfunction or any inadequacy of a device with respect to its identity, 
quality, durability, reliability, safety or performance and includes misuse or use 
errors and inadequate labeling. A device deficiency is something that happens to 
a device or is related to device performance, whereas an adverse event happens 
to a participant. A device deficiency may occur independently from an AE, or 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 45 
along with an AE. An AE may occur without a device deficiency or there may be 
an AE related to a device deficiency.   
Note: for reporting purposes, sites will not be asked to distinguish between device 
complaints and malfunctions.  
For any event where there is suspicion that the study device is involved, the 
Sponsor will request that the investigator return the device for evaluation. 
All device complaints or malfunctions involving any investigational component of 
the Omnipod Horizon™ System used in the study will be reported to the Sponsor 
within 5 business days of knowledge of the deficiency and documented on an 
appropriate eCRF. All study product associated with a reported device deficiency 
(PDM, Pod, and CGM) should be retained at the clinical site and returned to the 
Sponsor or CGM manufacturer for investigation and analysis. 
11.3.2 Reportable Adverse Events 
Adverse events will be assessed on an ongoing basis throughout the study. 
Adverse event reporting will begin at the start time of the standard therapy phase 
(i.e., insertion of the CGM sensor) and continue through the hybrid closed-loop 
phase until the subject’s participation has ended. All adverse events must be 
followed until resolution, or until the AE has stabilized, or until the study has been 
completed. 
Pre-existing medical conditions or symptoms observed prior to the start time of the 
standard therapy phase will not be recorded as an AE and should be collected in 
the subject’s medical history. In the event there is a change (i.e., worsening) in the 
pre-existing medical condition or symptoms after enrollment meeting the criteria of 
a reportable adverse event, then an AE must be reported. 
For this protocol, a reportable adverse event includes any untoward medical 
occurrence that meets one of the following criteria: 
1. An SAE 
2. An ADE unless excluded from reporting in Hypoglycemic Events and 
Hyperglycemic/Ketotic Events sections below 
3. An AE occurring in association with a study procedure 
4. An AE not related to a study device issue which leads to temporary or 
permanent discontinuation of the study device 
5. An AE that affects the participant’s ability to complete any study 
procedures 
6. An AE for which a visit is made to a hospital emergency department   
7. Hypoglycemic Events as defined below 
8. Hyperglycemic/Ketotic Events as defined below.  
Skin reactions from sensor or pod placement are only reportable if severe and/or 
required treatment. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 46 
For the purpose of this protocol, mild symptoms of hypoglycemia and 
hyperglycemia (i.e., clinically non-significant) or blood glucose values out of the 
normal range (whether or not they resulted in delayed meals or correction 
boluses) will not be reported as AEs unless determined to meet the reportable 
criteria in the Hypoglycemic Events and Hyperglycemic/Ketotic Events sections 
below. 
All reportable AEs—whether volunteered by the participant, discovered by study 
personnel during questioning, or detected through physical examination, 
laboratory test, or other means—will be reported on an AE eCRF.  
11.3.3 Hypoglycemic Events 
Hypoglycemia is only reportable as an adverse event when one of the following 
criteria is met:   
• 
Severe Hypoglycemia: The event required assistance of another person 
due to altered consciousness, and required another person to actively 
administer carbohydrate, glucagon, or other resuscitative actions.25 This 
means that the participant was impaired cognitively to the point that he/she 
was unable to treat himself/herself, was unable to verbalize his/her needs, 
was incoherent, disoriented, and/or combative, or experienced seizure or 
loss of consciousness. These episodes may be associated with sufficient 
neuroglycopenia to induce seizure or loss of consciousness. If plasma 
glucose measurements are not available during such an event, 
neurological recovery attributable to the restoration of plasma glucose to 
normal is considered sufficient evidence that the event was induced by a 
low plasma glucose concentration.  
• 
Hypoglycemia resulting in an SAE that may not otherwise meet the 
definition of Severe Hypoglycemia defined above.  
 
When a hypoglycemic event meets the above reporting requirements, an Adverse 
Event Form should be completed. A severe hypoglycemia event should be 
considered a serious adverse event and follow the SAE reporting requirements. 
 
11.3.4 Hyperglycemic/Ketotic Events 
Hyperglycemia is only reportable as an adverse event when any one of the 
following criteria is met:   
• 
The event involved DKA, as defined by the Diabetes Control and 
Complications Trial (DCCT)24 and described below 
• 
Evaluation or treatment was obtained at a health care provider facility for 
an acute event involving hyperglycemia or ketosis, or the participant 
contacted the site and received guidance on how to manage the 
hyperglycemia/ketosis 
• 
Prolonged hyperglycemia: defined as meter BG ≥300 mg/dL and ketones 
>1.0 mmol/L 
• 
Hyperglycemia resulting in an SAE that may not otherwise meet the above 
criteria 
 
Hyperglycemic events are classified as DKA24 if all of the following are present: 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 47 
• 
Symptoms such as polyuria, polydipsia, nausea, or vomiting; 
• 
Serum ketones >1.5 mmol/L or large/moderate urine ketones; 
• 
Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate 
<15; and 
• 
Treatment provided in a health care facility 
 
When a hyperglycemia/ketotic event meets the above reporting requirements, 
Adverse Event Form should be completed.  
 
Events meeting DKA criteria should be considered a serious adverse event and 
follow the SAE reporting requirements. Hyperglycemia events not meeting criteria 
for DKA generally will not be considered as serious adverse events unless one of 
the SAE criteria above is met. 
 
11.3.5 Relationship of Adverse Event to Investigational Device 
The investigator will be responsible for making a determination on the causal 
relationship of the AE. Specifically, the investigator will report whether the AE was 
related to study procedures and/or related to the investigational device. 
To ensure consistency of adverse event causality assessments, investigators 
should apply the following general guideline when determining whether an 
adverse event is related: 
The causal relationship to the study procedures and the investigational device for 
each adverse event will be rated as follows:  
• 
Unrelated: The event is not related to the procedures or the investigational 
device.  
• 
Possibly Related: The temporal sequence is such that the relationship is 
not unlikely or there is no contradicting evidence that can reasonably 
explain the subject’s condition. There is a possibility of any relation 
between the event and the procedures or the investigational device.  
• 
Related: The temporal sequence is relevant or the event abates upon 
completion of the procedure/ investigational device, or the event cannot be 
reasonably explained by the subject’s condition or comorbidities. The 
event is related or most likely associated with the procedures or the 
investigational device. 
 
11.3.6 Severity (Intensity) of Adverse Events 
The severity (intensity) of an adverse event will be rated on a three-point scale: (1) 
mild, (2) moderate, or (3) severe. A severity assessment is a clinical determination 
of the intensity of an event. Thus, a severe adverse event is not necessarily 
serious. For example, itching for several days may be rated as severe, but may 
not be clinically serious. 
• 
MILD: Usually transient, requires no special treatment, and does not 
interfere with the participant’s daily activities. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 48 
• 
MODERATE: Usually causes a low level of inconvenience, discomfort or 
concern to the participant and may interfere with daily activities but is 
usually ameliorated by simple therapeutic measures and participant is able 
to continue in study. 
• 
SEVERE: Interrupts a participant’s usual daily activities, causes severe 
discomfort, may cause discontinuation of study device, and generally 
requires systemic drug therapy or other treatment. 
 
11.3.7  Outcome of Adverse Events 
The outcome of each reportable adverse event will be classified by the 
investigator as follows: 
• 
RECOVERED/RESOLVED - The participant recovered from the AE/SAE 
without sequelae. Record the AE/SAE stop date. 
• 
RECOVERED/RESOLVED WITH SEQUELAE - The event persisted and 
had stabilized without further anticipated change in the event status. 
Record the AE/SAE stop date. 
• 
FATAL - A fatal outcome is defined as the SAE that resulted in death. Only 
the event that was the cause of death should be reported as fatal.  
AEs/SAEs that were ongoing at the time of death; however, were not the 
cause of death, will be recorded as “resolved” at the time of death. 
• 
NOT RECOVERED/NOT RESOLVED (ONGOING) - An ongoing AE/SAE 
is defined as the event was ongoing with an undetermined outcome. 
• 
An ongoing outcome will require follow-up by the site in order to 
determine the final outcome of the AE/SAE or until participant 
completes the study. 
• 
The outcome of an ongoing event at the time of death that was not the 
cause of death, will be updated and recorded as “resolved” with the 
date of death recorded as the stop date. 
• 
UNKNOWN - An unknown outcome is defined as an inability to access the 
participant or the participant’s records to determine the outcome (for 
example, a participant that was lost to follow-up). 
 
If any UADEs are ongoing when a participant completes the study (or withdraws), 
the subject will continue to be followed until the event resolves or has no prospect 
of improvement or change, even after the participant has completed all applicable 
study visits/contacts, unless that subject has withdrawn their consent. For all other 
reportable adverse events, data collection will end at the time the participant 
completes the study. Note: Participants should continue to receive appropriate 
medical care for an adverse event after their participation in the study ends.  
 
11.4 Reportable Device Issues 
Device complaints and malfunctions will be reported except in the following 
circumstances. These occurrences are expected and will not be reported on a 
Device Deficiency Form: 
• 
CGM sensor or Pod lasting fewer days than expected per manufacturer 
• 
CGM tape or Pod adherence issues 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 49 
• 
Battery lifespan deficiency due to inadequate charging or extensive wireless 
communication 
• 
Intermittent device component disconnections/communication failures not 
requiring system replacement or workaround/resolution not specified in user 
guide/manual. 
• 
Device issues clearly addressed in the user guide manual that do not require 
additional troubleshooting 
 
11.5 Timing of Event Reporting 
SAEs possibly related or related to a study device or study procedures and 
UADEs must be reported to the Sponsor/CRO within 2 business days of the site 
becoming aware of the event. This can occur via phone or email, or by completion 
of the AE eCRF. If the form is not initially completed, it should be completed as 
soon as possible after there is sufficient information to evaluate the event. All 
other reportable AEs should be submitted by completion of the AE eCRF within 5 
business days of the site becoming aware of the event.  
Each principal investigator is responsible for reporting adverse events required by 
this protocol and abiding by any other reporting requirements specific to his/her 
Institutional Review Board or Ethics Committee.  
Upon receipt of a UADE report, the Sponsor will investigate the UADE and if 
indicated, report the results of the investigation to all participating investigators, 
overseeing IRBs, and the FDA within 10 business days of the Sponsor becoming 
aware of the UADE per 21CFR 812.46(b). Copies of the associated reports and 
correspondence with the investigators, regulatory authorities, and Sponsor must 
be retained with study records. 
The Medical Monitor must notify the DSMB of any UADEs and determine if the 
UADE presents an unreasonable risk to participants. If so, the Sponsor must 
ensure that all investigations, or parts of investigations presenting that risk, are 
terminated as soon as possible but no later than 5 working days after the Medical 
Monitor makes this determination and no later than 15 working days after first 
receipt notice of the UADE. 
Device deficiencies will be handled by the Sponsor or designee as described 
below. In the case of a Dexcom CGM transmitter or sensor device malfunction, 
information should be forwarded to Dexcom by the site personnel, to be handled 
by Dexcom’s complaint management system. 
If the subject is hospitalized because of or during the course of an SAE, then a 
copy of the hospital discharge summary must be requested for inclusion with the 
SAE documentation. In case of death, the investigator must make every effort to 
obtain a copy of the death certificate to submit to the Sponsor. When submitting 
copies of documentation, all subject identifying information must be redacted and 
only the unique subject number will be used to label the forms for identification 
purposes. 
For any event where there is suspicion that the study device is involved, the 
investigator will return the device for evaluation when possible. 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 50 
11.6 Safety Oversight 
The study Medical Monitor will review all adverse events that are reported during 
the study. SAEs will typically be reviewed within 24-hours of reporting.  Other AEs 
will typically be reviewed approximately weekly.  
A Data and Safety Monitoring Board (DSMB) will be informed of all cases of 
severe hypoglycemia and diabetic ketoacidosis irrespective of device relationship 
and all UADEs during the study and will review compiled safety data at periodic 
intervals. The DSMB also will be informed of any SADEs and ADEs not meeting 
criteria for a UADE if the Medical Monitor requests the DSMB review. The DSMB 
can request modifications to the study protocol or suspension or outright stoppage 
of the study if deemed necessary based on the totality of safety data available. 
Details regarding DSMB review will be documented in a separate DSMB Charter. 
 
11.7 Stopping Criteria 
11.7.1 Participant Discontinuation of Study Participation 
In the case of a UADE, use of the study device will be suspended while the 
problem is diagnosed. After assessment of the problem and any correction, use of 
the study device will not be restarted until approval is received from the IRB, 
DSMB, and FDA. 
Use of the study device by a participant will be discontinued if any of the following 
occur:  
• 
The investigator believes it is unsafe for the participant to continue on the 
intervention. This could be due to the development of a new medical 
condition or worsening of an existing condition; or participant behavior 
contrary to the indications for use of the device that imposes on the 
participant’s safety. 
• 
The participant requests that the treatment be stopped 
• 
Participant pregnancy 
• 
Two distinct episodes of DKA as defined above 
• 
Two distinct severe hypoglycemia events as defined above 
• 
One episode of DKA and one severe hypoglycemia event as defined 
above 
 
An additional requirement for continued study device use following a single DKA 
or severe hypoglycemia event will be that (1) the site investigator believes that 
the event is explainable, unlikely to recur, and that it is safe for the participant to 
continue to use the system and (2) the Medical Monitor concurs. If the Medical 
Monitor determines that the occurrence of the event indicates that it is not safe 
for the participant to continue to use the system, use will be discontinued, and the 
subject will be withdrawn from the study. 
 
11.7.2 Criteria for Suspending or Stopping Overall Study 
Stopping criteria for the entire study will be determined by an independent DSMB, 
who will assess the specific event rates for DKA and severe hypoglycemia from 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 51 
the study at specific timepoints relative to published rates from large, population-
based datasets.   
 
In consideration of adverse events rates occurring in this proposed the rates will 
be assessed relative to published rates from Foster et. al.10 and Miller et. al.26 to 
determine whether severe hypoglycemia or diabetic ketoacidosis are within 
expected rates during this study. Table 6:  T1D Exchange Rates of Severe 
Hypoglycemia and Diabetic Ketoacidosis10,26provides a summary of these 
published rates. 
Table 6:  T1D Exchange Rates of Severe Hypoglycemia and Diabetic 
Ketoacidosis10,26 
Adverse Event 
Frequency of subjects to experience ≥ 1 
event extrapolated from T1DX registry 
2016-2018, 2013-2014 
Severe hypoglycemia (loss of consciousness or 
seizure) 
4-5% < 18 years  
7% ≥ 18 years 
Diabetic ketoacidosis (overnight hospitalization) 
3-4% < 18 years   
2-3% ≥ 18 years  
 
For unanticipated adverse device effects (UADEs), the DSMB will determine 
whether the study should proceed or not based upon risk of additional serious 
adverse events and the underlying root cause analysis of the UADE.   
 
Study activities could be similarly suspended if the manufacturer of any 
component of the investigational study device requires stoppage of device use for 
safety reasons (e.g. product recall).  
 
The affected study activities may resume if the underlying problem can be 
corrected by a protocol or system modification that will not invalidate the results 
obtained prior to suspension.  
 
The study Medical Monitor will review all adverse events that are reported during 
the study, and the DSMB will review all cases of severe hypoglycemia, DKA and 
UADEs as well as compiled safety data at periodic intervals. The Medical Monitor 
and/or DSMB may recommend suspension of study activities or stoppage of the 
study to the Sponsor if deemed necessary based on the totality of safety data 
available. 
11.8 Data Safety Monitoring Board (DSMB) 
The DSMB will be established prior to the first enrollment and consist, at a 
minimum, of two physicians and one statistician independent from the Sponsor 
and study. The physicians will have relevant therapeutic and medical expertise. 
The DSMB will determine the stopping criteria for the entire study and review 
Severe Hypoglycemia and DKA as well as compiled safety data at periodic 
intervals to determine if the stopping rules apply. Compiled safety data may 
include listings of protocol deviations, device deficiencies, subject terminations, 
and subject withdrawals. In addition, the DSMB members will be notified upon the 
occurrence of any UADEs to determine whether the study should proceed or not 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 52 
based upon risk and may request an ad hoc meeting to discuss. At minimum, the 
DSMB will conduct reviews after 16 subjects from the prepivotal study have 
completed a minimum of 10-days of hybrid closed-loop and at the conclusion of 
the prepivotal study. Further reviews will occur during the pivotal study, as 
defined, in the pivotal study protocol.  Additional reviews during the study may be 
conducted at any time based on the request of the DSMB, Sponsor or Medical 
Monitor. At the conclusion of each meeting, the DSMB will make a 
recommendation to the Sponsor concerning the continuation, modification, and/or 
termination, of the study and/or a statement regarding their overall assessment of 
device safety and continuation of the pivotal study. The final decision regarding 
the continuation, modification or termination of the study will reside with the 
Sponsor. Responsibilities, qualifications, membership and committee procedures, 
including the final stopping rules, will be outlined in the DSMB Charter. 
 
11.9 Medical Monitor 
An independent Medical Monitor will be responsible for individual and timely 
review of adverse events as defined below. The Medical Monitor will be a 
physician with relevant therapeutic and medical expertise that is not participating 
as an Investigator in the study and does not have a financial, scientific, or other 
conflict of interest with the clinical study. 
 
Specific responsibilities of the Medical Monitor include:  
 
• 
Review of all adverse events reported during the study 
• 
Review all serious study procedure-related and/or investigational device-
related adverse events to determine if the adverse event warrants 
consideration as a UADE and facilitate the reporting of UADEs if applicable  
• 
Adjudicate the following(a) all SAEs; (b) any events of Diabetic Ketoacidosis 
or Severe Hypoglycemia; (c) all AEs reported by the site as related or 
possibly related to the investigational device; and/or (d) any additional 
events as requested by the Sponsor or DSMB.  
• 
The specified events will be adjudicated to determine: 
o event relatedness to the study procedures and/or the 
investigational device 
o event categorization and assess seriousness and severity 
o whether an adverse event is anticipated or unanticipated 
The adjudication decision of the Medical Monitor will be used for the final 
classification of events, including relatedness to the study procedures and/or the 
investigational device, for the determination of safety endpoints and for all 
regulatory reports, product labeling, and publications or presentations. 
 
The Medical Monitor’s roles and responsibilities are described in the Safety 
Management Plan (SMP).  
 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 53 
12 STATISTICAL CONSIDERATIONS 
12.1 Objectives and Endpoints 
12.1.1 Safety Objective 
The safety objective of the study is to evaluate the safety of the Omnipod 
Horizon™ System in patients with type 1 diabetes. 
12.1.1.1 Primary Safety Endpoint 
Proportion of subjects with serious device-related adverse events. 
 
12.1.1.1 Secondary Safety Endpoints 
• 
Proportion of subjects with severe hypoglycemia during hybrid closed-
loop 
• 
Proportion of subjects with diabetic ketoacidosis (DKA) during hybrid 
closed-loop 
 
12.1.2 Primary Effectiveness Objective 
The primary effectiveness objective of this study is to evaluate the effectiveness of 
the Omnipod Horizon™ System 
 
12.1.2.1 Primary Effectiveness Endpoints 
The primary effectiveness objective will be evaluated by comparing the 
percentage of time in range (70-180 mg/dL) during hybrid closed-loop compared 
to the standard therapy for: 
 
• 
Target BG challenge days (approximately hybrid closed-loop days 1-9) 
• 
Non-challenge days (approximately hybrid closed-loop days 10-14) 
• 
Overall (hybrid closed-loop days 1-14) 
 
12.1.3 
Secondary Effectiveness Objective 
The secondary objective of the study is to evaluate additional glycemic measures 
of effectiveness of the Omnipod Horizon™ System. 
12.1.4 
Secondary Effectiveness Endpoints 
The secondary objective will be evaluated using the following per subject 
endpoints: 
 
• 
Glucose metrics from system CGM during the hybrid closed-loop phase will 
be compared to the standard therapy phase during the day, overnight, and 
overall:  
 
• 
Mean glucose 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 54 
• 
% of time in range 70-180 mg/dL 
• 
% of time in range 70-140 mg/dL 
• 
% of time > 180 mg/dL 
• 
% of time ≥ 250 mg/dL 
• 
% of time ≥ 300 mg/dL 
• 
% of time < 70 mg/dL 
• 
% of time < 54 mg/dL 
• 
Standard deviation 
• 
Coefficient of variation 
 
• 
GMI based on overall mean glucose 
• 
Percentage of time in hybrid closed-loop as proportion of overall device 
usage time 
• 
Insulin requirements during the hybrid closed-loop phase will be compared to 
the standard therapy phase: 
 
• 
Total daily insulin (TDI) (units, units/kg) 
• 
Total daily basal insulin (units, units/kg) 
• 
Total daily bolus insulin (units, units/kg) 
 
12.2 Sample Size 
This is a single-arm, multi-center, prospective study. The sample size is not 
hypothesis-driven and was chosen to provide adequate information on the 
device’s safety and performance. 
12.3 Analysis Sets 
The following analysis sets are planned for the study: 
12.3.1 
ITT (Intention to Treat) Analysis Set 
The ITT analysis set includes all subjects that are enrolled in the study. All safety 
analyses (other than primary analysis of primary safety endpoints) will be based 
on the ITT analysis set. 
12.3.2 
mITT (modified Intention to Treat) Analysis Set 
The modified Intention to Treat (mITT) analysis set is a subset of the ITT analysis 
set. The mITT analysis set will consist of subjects who have entered the hybrid 
closed-loop phase of the study successfully. The mITT analysis set will be used as 
the primary analysis for the primary and secondary endpoints and other clinical 
outcome data. 
12.3.3 
PP (Per-Protocol) Analysis Set 
The Per-Protocol (PP) analysis set is a subset of the mITT analysis set. Subjects 
will be included in the PP analysis set if they have a minimum of 80% system use 
during the hybrid closed-loop phase inclusive of Manual and Automated Modes 
over a duration of 14-days and have completed the study without major protocol 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 55 
deviations. The PP analysis set will be used as supportive analysis for the 
effectiveness endpoints. The following will be considered major protocol 
deviations: 
• 
Major inclusion/exclusion criterion deviation 
• 
Significant protocol non-compliance that may confound the study objective 
data (e.g., use of prohibited medications) 
The list of subjects excluded from the PP analysis set will be determined prior to 
analysis. If the PP analysis set does not differ from the mITT analysis set, 
separate analyses will not be presented. 
12.4 Analysis of Primary and Secondary Effectiveness Endpoints 
Summary statistics will be presented by age cohort for all endpoints, stratified by 
time points of interest (e.g., day vs. night, overall). The effectiveness endpoints will 
be summarized for modified Intention to Treat (mITT) and Per Protocol (PP) 
analysis sets. If the PP analysis set does not differ from the mITT analysis set, 
separate analyses will not be presented. The data may be stratified by phase of 
the study, where the data collected in the standard therapy phase of the study 
(after adjustment of parameters, if necessary) will be compared to the data 
collected in the hybrid closed-loop phase of the study. The primary effectiveness 
endpoint will also by presented by existing Dexcom G6 use at the time of 
screening (users and non-users). 
The primary effectiveness endpoint and the secondary effectiveness endpoints 
that summarize time in specific glycemic ranges will be calculated from device 
data outputs as follows: 
100 × # 𝑜𝑓 𝐶𝐺𝑀 𝑟𝑒𝑐𝑜𝑟𝑑𝑠 𝑖𝑛 𝑟𝑎𝑛𝑔𝑒 
# 𝑜𝑓 𝑒𝑣𝑎𝑙𝑢𝑎𝑏𝑙𝑒 𝐶𝐺𝑀 𝑟𝑒𝑐𝑜𝑟𝑑𝑠= 𝑇𝐼𝑅% 
All statistical comparisons will be conducted at a two-side significance level of 5%. 
Since the results of endpoint analyses are not used to support clinical claims, no 
adjustment for multiplicity will be included. Data from all sites will be pooled for all 
analyses; no separate analyses by site or formal testing of poolability will be 
performed. 
12.5 Additional Data Analyses 
Following the upload of controller data into the database, the data will be made 
available to Sponsor representatives for periodic reviews. Reviews of the 
controller data will be conducted to identify any anomalies and to confirm the 
algorithm appears to be functioning as expected. These reviews, including any 
findings, will be documented. Unless potential safety concerns are identified, the 
results of such reviews will not be shared with study sites or subjects and thus, will 
not impact study outcomes. Should a potential safety concern be identified, sites 
may be notified as appropriate to ensure subject safety and measures may be 
taken to address the issue such as, but not limited to, changes to the protocol 
and/or device. Any resulting device deficiencies will be reported, if applicable. A 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 56 
brief summary of the controller data reviews will be included in the final clinical 
study report. 
 
12.6 Safety Analyses 
12.6.1 
Evaluation of Adverse Events  
All adverse events reported over the course of the study will be summarized and 
tabulated by study phase (standard therapy or hybrid closed-loop), event 
category, seriousness, severity, and relationship to the study and the 
investigational device. For the purposes of summarization, an event will be 
considered “Related” if the relationship was deemed as “Possibly Related” or 
“Related”. In cases where the same event is reported more than once per subject, 
the event will only be counted once in the incidence table(s).  
Adverse events leading to death or to discontinuation from the study will be listed 
separately. A listing of all adverse events will be provided. The primary safety 
endpoint will also be presented by existing Dexcom G6 use at the time of 
screening (users and non-users). 
12.6.2 Evaluation of Device Deficiencies  
Device deficiencies will be tabulated and listed in a manner similar to the methods 
described for adverse events. Any device deficiency leading to an AE or to study 
termination will be listed separately. 
12.7 Baseline Characteristics 
The distribution of each baseline characteristic or demographic parameter of 
interest (such as age, gender, medical history, etc.) will be presented. Data on all 
enrolled subjects will be presented. Continuous variables will be summarized 
using count, mean, median, standard deviation, and range. Categorical variables 
will be summarized using counts and percentages. 
12.8 General Statistical Methods 
Standard statistical methods will be employed to analyze all data. All data 
collected in this study will be documented using summary tables and subject data 
listings. Unless otherwise noted, all p-values will be considered significant at a 
two-sided significance level of 5%. Continuous variables will be summarized using 
descriptive statistics, including count, mean, median, standard deviation (SD), 
minimum and maximum. Where appropriate, 95% two-sided confidence intervals 
for the means or medians will be presented. If the observed data are found not to 
follow a normal distribution, appropriate non-parametric methods may be 
employed. Categorical variables will be summarized by frequencies and 
percentages. Unless explicitly stated otherwise, percentages will utilize a 
denominator corresponding to the number of unique subjects. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 57 
12.9 Missing Data 
All practical monitoring and follow-up steps will be taken to ensure complete and 
accurate data collection. It is anticipated that the rate of missing data would be 
very low due to the limited duration of the study. All analyses will be based on 
available data only; no imputation for missing data is planned. 
12.10 Statistical Software 
The statistical software package SAS® 9.4 or later will be used for all the data 
derivations, summarization, data listings and statistical analyses. Additional 
software such as Splus or R may be used for graphics or validation as 
appropriate. 
13 DATA HANDLING AND QUALITY ASSURANCE 
Data in this study will be collected on Electronic Case Report Forms as well as via 
electronic device outputs. 
 
13.1 Electronic Case Report Forms (eCRFs) 
Study data are collected through a combination of subject electronic CRFs 
(eCRFs) and electronic device data files. eCRF Data will be recorded in a  21 CFR 
Part 11 compliant database that will reside on a central server accessible via the 
Internet. 
Electronic data files contain the primary source data for study devices.  When data 
are directly collected in the eCRFs, this will be considered source data.  When 
data is not directly collected in the eCRFs, electronic or paper documents 
containing source data that is transcribed into the eCRF are the source. 
The investigator is responsible for the accuracy and completeness of data 
reported on the eCRFs. Each set of subject eCRFs must be reviewed and signed 
by the investigator in the EDC system. The investigator also agrees to maintain 
accurate source documentation supporting the data. When pertinent supportive 
information is available for data entered directly into the eCRFs, this supporting 
documentation will also be maintained.  Source documents may include chart 
notes, laboratory reports, images, study specific source worksheets, eCRFs, 
device data files, etc. 
13.2 Electronic Device Outputs 
13.2.1 
PDM Data 
This study will utilize insulin delivery data from the PDM device. All insulin delivery 
data and all CGM readings from the hybrid closed-loop phase will be stored on the 
PDM and exported to Insulet Cloud. Data will be saved in a compatible format that 
will be extractable for statistical analysis purposes. Data from the hybrid closed-
loop phase will be uploaded to the database and used for analysis.  

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 58 
13.2.2 
CGM Data 
This study will utilize CGM measurements from the CGM device. All CGM 
readings from the hybrid closed-loop phase will be stored on the controller. CGM 
data will be saved in a compatible format that will be extractable for statistical 
analysis purposes. CGM data from the standard therapy phase will be uploaded to 
the database and used for comparative analysis.  
13.2.3 
BG and Ketone Meter Data 
This study will also utilize measurements from a BG and ketone meter. BG 
fingerstick measurements will recorded in a compatible format that will be 
extractable for statistical analysis purposes. Ketone meter data, in any format, will 
be uploaded to the database.  
13.3 Subject Identifiers 
All data used in the analysis and reporting of the study will be without identifiable 
reference to the subject. Only the unique subject number will be used to identify 
subject data submitted to the Sponsor, and only the investigating clinical site will 
be able to link the unique subject ID to the subject’s name. 
13.4 Monitoring Responsibilities 
This study will be monitored for compliance with the protocol and applicable 
regulatory requirements. A study specific monitoring plan will specify the minimum 
frequency, scope, and general conduct of monitoring visits as well as identify any 
relevant study-specific monitoring responsibilities. 
Monitors for this study will be qualified by education, experience and training. The 
monitor will report to the Sponsor any non-compliance with the protocol, 
applicable regulations, or any conditions imposed by the IRB or local regulatory 
authority. If compliance cannot be secured, device shipments to the Investigator 
may be discontinued and the Investigator’s participation in the study terminated. 
Investigators and clinical site coordinators are expected to make source files and 
other records and reports available to the monitors as required. 
13.5 Inspection of Records 
The Sponsor or its designee may perform quality assurance site and study file 
audits. Investigators and institutions involved in the study will permit trial-related 
monitoring, audits, IRB review, and regulatory inspection by providing direct 
access to all study records. In the event of an audit or inspection, the investigator 
agrees to allow the Sponsor, representatives of the Sponsor, the FDA, or other 
regulatory authorities access to all study records. 
The investigator should promptly notify the Sponsor of any study inspections 
scheduled by the regulatory authorities and promptly forward copies of any audit 
reports received to the Sponsor. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 59 
13.6 Study Record Retention 
Records and reports must remain on file at the investigational site for a minimum 
of two years after the later of either the completion/termination of the study or the 
date of market approval for the indication being studied. They may be discarded 
only upon approval from the Sponsor. The Principal Investigator must contact the 
Sponsor before destroying any records and reports pertaining to the study to 
ensure that they no longer need to be retained. In addition, the Sponsor must be 
contacted if the investigator plans to leave the investigational site to ensure that 
arrangements for a new investigator or records transfer are made prior to 
investigator departure. 
13.7 Device Accountability 
Investigators will be responsible for investigational device accountability, 
reconciliation and records maintenance throughout the course of the investigation. 
Accountability records will include receipt, use and final disposition of 
investigational product.  
Study devices must be stored according to the conditions set forth for the device 
on the label in a controlled, locked area. All device shipment records (packing 
lists, etc.) must be maintained at the clinical site.  
The study monitor will verify accountability of the study devices during routine 
monitoring visits to the clinical site. 
14 STUDY ETHICS AND CONDUCT 
14.1 Role of the Sponsor 
As the Sponsor of this clinical study, Insulet has the overall responsibility for the 
conduct of the study, including assurance that the study meets the requirements 
of the appropriate regulatory bodies. In this study, the Sponsor will have certain 
direct responsibilities and may delegate certain study tasks to the Contract 
Research Organization (CRO). 
14.2 Ethical Conduct of the Study 
The investigation will be conducted according to the applicable FDA regulations 
(21CFR 812, 56, 54, 50). The investigator will conduct all aspects of this study in 
accordance with all state, and local laws or regulations. 
14.3 Institutional Review Board (IRB) 
Federal regulations (21 CFR 812) require that approval be obtained from an IRB 
prior to participation of subjects in research studies. Prior to subject enrollment, a 
signed copy of the IRB approval letter must be submitted to the Sponsor. In 
addition, the protocol, informed consent, advertisements to be used for subject 
recruitment, and any other written information regarding this study to be provided 
to the subject must be approved by the IRB. Documentation of all IRB approvals 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 60 
will be maintained by the clinical site and will be available for review by the 
Sponsor or its designee. 
All IRB approvals should be signed by the IRB chairperson or designee and must 
identify the IRB by name and address, the clinical protocol by title and/or protocol 
number, and the date approval was granted. 
The Investigator is responsible for submitting and obtaining initial and continuing 
review of the trial at intervals not exceeding 1 year or as otherwise directed by the 
IRB. The investigator must supply the Sponsor, or its designee written 
documentation of continued review of the study. 
14.4 Informed Consent 
A written informed consent in compliance with 21 CFR 50 shall be obtained from 
each subject prior to participating in the study or performing any unusual or non-
routine procedure that involves risk to the subject. An informed consent form (ICF) 
template will be provided by the Sponsor or designee to investigative clinical sites. 
If any institution-specific modifications to study-related procedures are proposed 
or made by the clinical site, the consent must be reviewed by the Sponsor prior to 
IRB submission. Once reviewed, the consent will be submitted by the investigator 
to their IRB for review and approval prior to the start of the study. 
Before recruitment and enrollment, each prospective subject will be given a full 
explanation of the study and be allowed to read the approved ICF. Once the 
investigator or designee is assured that the subject understands the implications 
of participating in the study, the subject will be asked to give consent to participate 
in the study by signing the ICF. 
The investigator or designee shall provide a copy of the signed ICF to the subject. 
The original form shall be maintained in the subject binder at the clinical site. 
14.5 Confidentiality 
All information and data sent to the Sponsor concerning study subjects or their 
participation in this trial will be considered confidential. Only authorized personnel 
will have access to these confidential files. All records will be kept in secure 
storage areas and on password-protected computers.  
This includes, but is not limited to the following: 
• 
Subjects will be identified on all eCRFs by a unique subject ID 
• 
eCRFs are confidential documents and will only be available to the Sponsor 
(including delegates, such as CRAs), DSMB, Medical Monitor, CRO, the 
investigator and study staff, and if requested, to the IRB or regulatory 
authorities. The investigator will maintain, as part of the investigation file, a 
list identifying all subjects entered into the study. 
All laboratory specimens, evaluation forms, reports, and other records will be 
identified in a manner designed to maintain subject confidentiality. Clinical 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 61 
information will not be released without the written permission of the subject, 
except as necessary for monitoring and auditing by the Sponsor, its designee, the 
FDA, or the IRB. 
The investigator and all clinical site staff involved in this study may not disclose (or 
use for any purpose other than performance of the study), any data, record, or 
other unpublished confidential information disclosed to those individuals for the 
purpose of the study. Prior written agreement from the Sponsor or its designee 
must be obtained for the disclosure of any said confidential information to other 
parties. 
14.6 Modification of the Protocol 
Any changes in this research activity, except those necessary to remove an 
apparent immediate hazard to the subject, must be reviewed and approved by the 
Sponsor. The protocol amendment(s) must be signed by the investigator and 
approved by the IRB before implementation. The protocol amendment(s) will be 
filed with the appropriate regulatory agency(s) having jurisdiction over the conduct 
of the study. 
Substantial changes will require approval from the Sponsor, FDA, and IRB prior to 
implementation. 
14.7 Protocol Deviations 
The investigator will not deviate from the protocol without prior written approval 
from the Sponsor except in medical emergencies or in unforeseen, isolated 
instances where minor changes are made that will not increase the subject’s risk 
or affect the validity of the trial. In medical emergencies, prior approval for protocol 
deviations will not be required, but the Sponsor must be notified within 2 working 
days of the incident. Periodic monitoring of protocol compliance will be performed 
for each clinical site. The Sponsor has the right to suspend enrollment at clinical 
sites deemed to have excessive protocol compliance issues. 
All deviations related to study inclusion or exclusion criteria, conduct of the study, 
subject management or subject assessment must be appropriately documented 
and reported. Other protocol deviations to be considered include non-adherence 
to the protocol that results in a significant additional risk to the subject, or non-
adherence to FDA regulations.  
The investigator must document and explain any protocol deviation in the 
subject’s source documentation. The IRB should be notified of all protocol 
deviations in a timely manner. Protocol deviations should be reported to the IRB 
periodically, according to their requirements. Deviations will also be reviewed by 
the monitor during clinical site visits and those observations may be discussed 
with the investigator. 
The Sponsor will evaluate circumstances where the investigator deviates from the 
study protocol and will retain the right to remove either the investigator or the 
investigational clinical site from the study. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 62 
14.8 Study Reporting Requirements 
By participating in this study, the investigator agrees to submit SAE reports 
according to the timeline and method outlined in this protocol. In addition, the 
investigator agrees to submit annual reports to his/her IRB as appropriate. 
Upon completion or termination of the study, the principal investigator (PI) must 
submit a final written report to the Sponsor and IRB. The report must be submitted 
within 3 months (90 days) of completion or termination of the trial. 
The Sponsor will submit all reports required by the appropriate regulatory 
authorities, including unanticipated adverse device effects, withdrawal of IRB 
approval, list of current investigators, annual progress reports, recall information, 
final reports and protocol deviations. 
14.9 Selection of Investigators 
The Sponsor will select qualified investigators, ship devices only to participating 
investigators, obtain a signed Investigator’s Agreement and provide all 
investigators with the information and training necessary to conduct the study. 
14.9.1 
Financial Disclosure 
Investigators and sub-investigators are required to provide financial disclosure 
information to allow the Sponsor to submit the complete and accurate certification 
or disclosure statements required under 21 CFR 54. In addition, the investigator 
must notify the Sponsor promptly of any relevant changes that occur during the 
course of the study, at the completion of the study, and 1 year following the 
completion of the study. 
14.9.2 
Investigator Documentation 
Prior to beginning the study, the investigator will be asked to comply with 21 CFR 
812 by providing the following essential documents, including but not limited to: 
• 
An investigator-signed Investigator Agreement page of the protocol  
• 
An IRB approved informed consent, samples of clinical site advertisements 
for recruitment for this study, and any other written information regarding this 
study that is to be provided to the subject 
• 
IRB approval of the investigator, protocol, and acknowledgement of the user 
guide 
• 
Curricula vitae (CV) for the PI and each investigator participating in the 
study. Current licensure must be noted on the CV or a copy of the license 
provided. CVs must be signed and dated by the investigators within 1 year of 
study start-up, indicating that they are accurate and current. 
• 
Financial disclosure information (as stated above) and a commitment to 
promptly update this information if any relevant changes occur 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 63 
• 
Laboratory certifications and normal ranges for any local laboratories used 
by the clinical site. 
14.10 Clinical Site Training 
The training of appropriate clinical site personnel will be the responsibility of the 
Sponsor or its designee. To ensure proper device usage, uniform data 
collection, and protocol compliance, the Sponsor or designee will present formal 
training sessions to relevant clinical study site personnel. Clinical study 
personnel trained by the Sponsor may also train additional clinical study 
personnel at their site. The Sponsor reserves the right to enforce retraining for 
clinical sites who have demonstrated study or procedure compliance issues. 
Protocol-specific training will occur for all research personnel and key ancillary 
staff who will be involved in subject care. 
14.11 Device Use 
The Omnipod Horizon™ System consists of the following primary components: 
an Omnipod Horizon™ Pod, Omnipod Horizon™ Controller, and the iCGM. 
The Pod and PDM are intended for single use only.  
The Dexcom G6 CGM sensor (the component of the system that enters the 
skin) and the Dexcom G6 CGM transmitter (the component of the system that 
attaches to the sensor to transmit the signal) will both be single use only in this 
study. The Dexcom G6 CGM receiver will all be single use only in this study. 
Study blood glucose meters and ketone meters will not be cleaned or reused by 
subjects. A new meter will be used for each subject. 
14.12 Device Returns 
Any unused or damaged investigational devices or investigational devices 
related to a suspected deficiency or adverse event must be returned to the study 
Sponsor. To initiate the return, the clinical site will contact the Sponsor 
representative and provide the following information: 
• 
Part number/Lot number 
• 
Quantities 
• 
Tracking number 
14.13 Policy for Publication and Presentation of Data 
All data and results and all intellectual property rights in the data and results 
derived from the study will be the property of the study Sponsor, Insulet.  

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 64 
14.14 Sponsor or Regulatory Agency Termination of the Study 
Although the Sponsor intends to complete the study, the Sponsor reserves the 
right to stop the study at any time for clinical or administrative reasons, or if 
required by the local regulatory authority, with suitable written notice to the 
investigators and regulatory authorities as appropriate. 
Similarly, investigators may withdraw from the study by providing written 
notification to the Sponsor within 30 days of intent to withdraw. However, the 
Sponsor and investigators will be bound by their obligation to complete the 
follow-up of subjects already enrolled in the trial. Subjects must be followed 
according to the clinical protocol and information obtained during subject follow-
up shall be reported on the eCRF. 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 65 
REFERENCES 
1. Centers for Disease Control and Prevention. “Diabetes Report Card 2012” Atlanta, GA: 
Centers for Disease Control and Prevention, US Department of Health and Human Services 
(2012). 
2. Nathan, DM et al. “Intensive diabetes treatment and cardiovascular disease in patients with 
type 1 diabetes”. N. Engl. J. Med. 353: 2643-2653 (2005). 
3. Cryer, PE “Banting lecture. Hypoglycemia: the limiting factor in the management of IDDM”. 
Diabetes 43: 1378-1389, (1994). 
4. Weinstock RS et al. “Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 
diabetes: results from the T1D Exchange clinic registry” J Clin Endocrinol Metab. 
98(8):3411-3419 (2013). 
5. Livingstone SJ et al. “Estimated life expectancy in a Scottish cohort with type 1 diabetes 
2008-2010”. JAMA. Jan 6;313(1):37-44 (2015). 
6. Lind M et al. “Glycemic control and excess mortality in type 1 diabetes”. N Engl J Med. 
20;371(21):1972-1978 (2014). 
7. American Diabetes Association “Treatment Guidelines: Children and adolescents”. Diabetes 
Care 2015;38 (Suppl.):S70-S76 (2015). 
8. Nathan DM et al., “Translating the A1C assay into estimated average glucose values” 
Diabetes 31:1-6 (2008). 
9. Beck RW et al., “The T1D Exchange clinic registry“ J Clin Endocrinol Metab. 97(12):4383-
4389 (2012). 
10. Foster NC et al., “State of Type 1 Diabetes Management and Outcomes from the T1D 
Exchange in 2016-1018” Diabetes Technology Ther. Volume 21(2) pp. 66-72 (2019). 
11. Beck SE, “The content of Investigational Device Exemption and Premarket Approval (PMA) 
applications for Artificial Pancreas Device Systems” UCM259305 (November 9, 2012). 
12. Centers for Disease Control and Prevention – Physical Activity Basics: 
https://www.cdc.gov/physicalactivity/basics/index.htm?CDC_AA_refVal=https%3A%2F%2F
www.cdc.gov%2Fphysicalactivity%2Fbasics%2Fmeasuring%2Fheartrate.htm 
13. Buckingham B, Pinsker JE, Christiansen M, Schneider J, Peyser T, Dassau E, Lee JB, 
O'Connor J, Layne JE, Ly TT. Feasibility of Omnipod Hybrid Closed-loop Control in Adults 
With Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes 
Technol Ther. 2017;19(S1):A18-A19. 
14. Buckingham B, Forlenza GP, Schneider J, Peyser T, Dassau E, Lee JB, O'Connor J, Layne 
JE, Ly TT. Safety and Feasibility of Omnipod Hybrid Closed-Loop in Children Aged 6-12 
Years with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. 
Diabetes. 2017;66(S1A):LB34. 
15. Buckingham B, Forlenza GP, Schneider J, Peyser T, Dassau E, Lee JB, O'Connor J, Layne 
JE, Ly TT. Safety and Feasibility of Omnipod Hybrid Closed-Loop in Adolescents with Type 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 66 
1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes. 
2017;66(S1):A278. 
16. Forlenza GP, Buckingham B, Christiansen M, Wadwa RP, Peyser T, Lee JB, O'Connor J, 
Dassau E, Layne JE, Ly TT. Performance of Omnipod Personalized Model Predictive 
Control Algorithm With Moderate Intensity Exercise and Variable Setpoints in Adults With 
Type 1 Diabetes. Diabetes Technol Ther. 2018;20(S1):A56-A57. 
17. Buckingham B, Christiansen M, Forlenza GP, Wadwa RP, Peyser T, Lee JB, O'Connor J, 
Dassau E, Layne JE, Ly TT. Performance of Omnipod Personalized Model Predictive 
Control Algorithm With Specific Meal Challenges in Adults With Type 1 Diabetes. Diabetes 
Technol Ther. 2018;20(S1):A12-A13. 
18. Buckingham BA, Christiansen MP, Forlenza GP, Wadwa RP, Peyser TA, Lee JB, O'Connor 
J, Dassau E, Huyett LM, Layne JE, Ly TT. Performance of the Omnipod Personalized Model 
Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. 
Diabetes Technol Ther. 2018;20(9):585-595. 
19. Buckingham BA, Forlenza GP, Pinsker JE, Christiansen MP, Wadwa RP, Schneider J, 
Peyser TA, Dassau E, Lee JB, O'Connor J, Layne JE, Ly TT. Safety and feasibility of the 
OmniPod hybrid closed-loop system in adult, adolescent, and pediatric patients with type 1 
diabetes using a personalized model predictive control algorithm. Diabetes Technol Ther. 
2018;20(4):257-262. 
20. Buckingham B, Sherr J, Forlenza GP, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System Over 
5 Days of Outpatient Use in Adults with Type 1 Diabetes. Diabetes. 2018;67(S1):A55. 
21. Forlenza GP, Buckingham B, Sherr J, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in 
Adolescents with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes. 
2018;67(S1):A369. 
22. Sherr J, Forlenza GP, Buckingham B, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in 
Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes. 
2018;67(S1):A369. 
23. Forlenza GP, Buckingham BA, Christiansen MP, et al. Performance of Omnipod 
Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults 
with Type 1 Diabetes. Diabetes Technol Ther. 2019. 
24. The Diabetes Control and Complications Trial Research Group. The effect of intensive 
treatment of diabetes on the development and progression of long-term complications in 
insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86. 
25. Seaquist et. al. Diabetes Care. Hypo and Diabetes 2013, IHSG Diabetes Care 2017 
26. Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, 
Tamborlane WV, T1D Exchange Clinic Network. Current state of type 1 diabetes treatment 
in the US: updated data from the T1D Exchange clinic registry. Diabetes Care. 
2015;38(6):971-8 
27. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 
2nd edition. Washington, DC: U.S. Department of Health and Human Services; 2018. 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 67 
28. ISO 14155:2011 (E), Clinical investigation of medical devices for human subjects – Good 
clinical practice, second edition 2011-02-01. 
29. Sherr J, Buckingham BA, Forlenza G, et al. Safety and Performance of the Omnipod Hybrid 
Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 
Days Under Free-Living Conditions. Diabetes Technol Ther. 2019. 
 
 

 
 
Omnipod 
Horizon™ Prepivotal Study Protocol V2.3 
Confidential 
Page | 68 
APPENDIX